IngentaConnect Table Of Contents: Biological Psychiatry

The ''high risk'' paradigm: childhood predictors of schizophrenic disorders
pp. 500-501(2)
Authors: Cornblatt B.A.; Obuchowski M.; Dworkin R.; Erlenmeyer-Kimling L.

Attention and sensory gating deficits in relatives of schizophrenic patients
pp. 501-501(1)
Authors: Freedman R.; Adler L.E.; Cawthra E.; Harris J.G.; McRae K.; Olincy A.; Ross R.G.; Sullivan B.; Waldo M.C.; Young D.

Information processing impairment: a clinical & neurodevelopmental perspective
pp. 501-501(1)
Authors: Braff D.L.; Geyer M.A.; Perry W.; Swerdlow N.R.

Risk and protective factors across the schizophrenia spectrum
pp. 501-501(1)
Authors: Siever L.J.; Buchsbaum M.; Cornblatt B.; Harvey P.; Bergman A.; Siegel B.; Hazlett E.; Callahan A.; New A.S.; Downhill J.

Schizophrenic disorders: neurodevelopmental and onset vulnerability factors
pp. 502-502(1)
Authors: McCarley R.W.; Shenton M.E.; O'Donnell B.F.; Dickey C.C.; Greene R.W.

Thyroid hormone action in the brain: hormonal crosstalk & other mechanisms in behavior
pp. 502-502(1)
Author: Chin W.W.

Neuroactive steroids
pp. 502-502(1)
Author: Paul S.M.

Molecular strategies for identifying the roles of steroids in behavior
pp. 502-503(2)
Author: Pfaff D.

Enhanced transmembrane signaling of 5-ht receptor in platelets of bipolar affective disorder subjects
pp. 503-503(1)
Authors: Friedman E.; Wang H.Y.; Markowitz P.

Genetic approaches to anorexia nervosa
pp. 503-503(1)
Author: Berrettini W.

The neurobiology of eating disorders
pp. 503-503(1)
Author: Leibowitz S.F.

Clinical studies supporting genetic research in anorexia nervosa
pp. 504-504(1)
Authors: Kaye W.; Halmi K.; Berrettini W.; Goldman D.; Strober M.; Plotnikov K.; Pollice C.; Lilenfeld L.; Fichter M.; Treasurer J.; Kaplan A.; Woodside B.

Astrocytes and brain energy metabolism: possible influence on eating behavior
pp. 504-504(1)
Author: Magistretti P.J.

Lymphocyte phospholipid methylation is altered in schizophrenia
pp. 504-505(2)
Authors: Deth R.C.; DuRand C.J.; Sharma A.; Liu D.

Regulation of adenosine- and G protein-mediated signalling in opiate dependence
pp. 505-505(1)
Authors: Kaplan G.B.; Leite-Morris K.A.; Sears M.T.; McClelland E.G.; Sethi R.K.

Differential patterns of dopamine receptor gene expression in schizophrenia
pp. 505-505(1)
Authors: Meador-Woodruff J.H.; Damask S.P.; Haroutunian V.; Powchik P.; Davis K.L.; Watson S.J.; Davidson M.

Dopamine transporter in schizophrenia: a progressive loss with age in the cingulate cortex
pp. 505-506(2)
Authors: Hitri A.; Wyatt R.J.

Effect of chronic ethanol treatment on hippocampal CA3 neurons
pp. 506-506(1)
Authors: Ownby R.L.; Mason B.J.

A polymorphism in tryptophan hydroxylase and irritable aggression in personality disorders
pp. 506-506(1)
Authors: New A.S.; Gelernter J.; Trestman R.L.; Mitropoulou V.; Siever L.J.

Abnormal D₃ pre-mRNA processing in chronic schizophrenia
pp. 506-507(2)
Author: Schmauss C.

GABA and the pathophysiology of schizophrenia: a neurodevelopmental perspective
pp. 507-507(1)
Authors: van Kammen D.P.; Petty F.; Kelley M.E.; Kramer G.L.; Yao J.K.; Gurklis J.A.; Peters J.L.

Childhood onset schizophrenia: new research
pp. 507-507(1)
Author: Rapoport J.L.

Post-traumatic stress disorder: a developmental perspective
pp. 507-507(1)
Author: Putnam F.

Suicidal states in children, adolescents, and young adults
pp. 507-508(2)
Author: Pfeffer C.

Developmental continuities in anxiety and anxiety disorders
pp. 508-508(1)
Author: Klein R.G.

Identification of OCD subtypes
pp. 508-508(1)
Authors: Leckman J.F.; McDougle J.C.; Goodman W.K.; Pauls D.L.

Neurobiological mechanisms of relapse
pp. 508-508(1)
Author: Self D.W.

Dopaminergic modulation of frontal activity: involvement in cocaine addiction
pp. 508-509(2)
Authors: Volkow N.D.; Fowler J.S.; Wang G.J.; Hitzemann R.; Lieberman J.; Angrist B.

Cortical circuits involved in cocaine sensitization during withdrawal
pp. 509-509(1)
Author: Hammer R.P.

Cocaine-related cues elicit craving and activate cortical circuits relevant to episodic memory
pp. 509-509(1)
Authors: London E.D.; Grant S.; Newlin D.; Villemagne V.; Phillips R.L.; Liu X.; Kimes A.S.; Contoreggi C.; Margolin A.

Brain imaging correlates of cue-induced cocaine craving
pp. 509-509(1)
Authors: O'Brien C.P.; Childress A.R.; McElgin W.; Mozley P.D.; Fitzgerald J.; Reivich M.

Late-onset schizophrenia
pp. 510-510(1)
Authors: Jeste D.V.; Palmer B.W.; Gladsjo J.A.; Evans J.D.; Symonds L.L.

Maintenance treatment in older schizophrenics
pp. 510-510(1)
Authors: Harris M.J.; Paulsen J.S.; Schalz A.C.; Jeste D.V.

Brain imaging in late-life onset schizophrenia
pp. 510-510(1)
Author: Pearlson G.D.

Alzheimer's-type pathology in schizophrenia with dementia
pp. 510-511(2)
Authors: Dwork A.J.; Keilp J.G.; Waniek C.; Liu D.; Susser E.; Kaufman M.A.; Prohovnik I.

Late paraphrenia, past and present
pp. 511-511(1)
Author: Roth M.

Neurosurgical procedures for refractory OCD
pp. 511-511(1)
Author: Jenike M.A.

Surgical therapies for Parkinson's Disease: embryonic nigral grafts and pallidal ablation
pp. 511-511(1)
Author: Eidelberg D.

Electroconvulsive therapy and the neuroanatomy of mood disorders
pp. 511-512(2)
Author: Sackeim H.

The use of light therapy in psychiatry
pp. 512-512(1)
Author: Rosenthal N.E.

Rapid transcranial magnetic stimulation (RTMS)--a potential new neuropsychiatric treatment
pp. 512-512(1)
Author: George M.S.

Neural network model successfully predicts amphetamine effects in new task
pp. 512-512(1)
Authors: Servan-Schreiber D.; Carter C.S.; Bruno R.; Cohen J.D.; Callaway E.

Assessment of striatal dopamine function in schizophrenia
pp. 513-513(1)
Authors: Breier A.; Su T.-P.; Weisenfeld N.; Elman I.; Adler C.; Malhotra A.K.; Pickar D.

What is the lowest effective dose of haloperidol? Evidence from PET studies
pp. 513-513(1)
Authors: Kapur S.; Remington G.; Jones C.; Roy P.; Reed K.; Houle S.; Zipursky R.B.

Optimal haloperidol dosage for first episode schizophrenia
pp. 513-513(1)
Authors: Wong J.; Zipursky R.B.; Beiser M.; Bean G.

D2 receptor occupancy in risperidone and clozapine-treated schizophrenics
pp. 513-514(2)
Authors: Su T.-P.; Breier A.; Coppola R.; Hadd K.; Elman I.; Adler C.; Malhotra A.K.; Watsky E.; Gorey J.; Weinberger D.; Pickar D.

Brain imaging to determine the effects of sertindole in schizophrenic patients
pp. 514-514(1)
Authors: Potkin S.; Zborowski J.; J. W.; Mack R.; Bera R.; Sebree T.; Aurang C.; Bunney W.

¹¹C NMSP receptor occupancy by clozapine and haloperidol in schizophrenic subjects
pp. 514-514(1)
Authors: Conley R.; M. Z.; D. W.; Tamminga C.

IBZM-SPECT shows low striatal D2 blockade under therapy with seroquel
pp. 514-515(2)
Authors: Tauscher J.; Kufferle B.; Neumeister A.; Asenbaum S.; Brucke T.; Podreka I.; Kasper S.

Reliability of a non-invasive [¹¹C]-raclopride scan to measure D₂- dopamine receptors
pp. 515-515(1)
Authors: Jones C.L.; Kapur S.; Hussey D.; K. C.; DaSilva J.; Wilson A.A.; Houle S.

IBZM SPECT measurement of D2 receptor occupancy by haloperidol and risperidone
pp. 515-515(1)
Authors: Knable M.B.; Heinz A.; Coppola R.; Gorey J.; Weinberger D.R.

rCBF changes in OCD patients receiving antidepressants
pp. 515-516(2)
Authors: Hoehn-Saric R.; Schlaepfer T.E.; Greenberg B.D.; McLeod D.R.; Pearlson G.D.

Altered response to intravenous D-fenfluramine during depression using [¹⁵O]-PET
pp. 516-516(1)
Authors: Meyer J.; Kennedy S.; Swinson R.; Houle S.; Brown G.

Disordered brain functional connectivity during hallucinations in a schizophrenic patient
pp. 516-516(1)
Authors: Silbereweig D.; Stern E.; Frith C.; Schnorr L.; Cahill C.; Jones T.; Frackowiak R.S.J.

Scopolamine effects on rCBF during human eyeblink conditioning
pp. 516-517(2)
Authors: Bahro M.; Schreurs B.G.; Sunderland T.; Molchan S.E.; McIntosh A.R.

In vivo brain pet responses and neuroendocrine alterations following serotonin release in depressed patients versus healthy controls
pp. 517-517(1)
Authors: Malone K.M.; Anjilvel S.; Campbell C.; S. L.; Mintun M.M.; Mann J.J.

¹⁹F magnetic resonance spectroscopy study of fluvoxamine
pp. 517-517(1)
Authors: Strauss W.; Dager S.R.; Layton M.L.; Hayes C.

FDG-PET predictors of response to behavioral versus pharmacotherapy in OCD
pp. 517-518(2)
Authors: Brody A.L.; Saxena S.; Schwartz J.M.; Stoessel P.; Baxter L.R.

Developmental morphology of the corpus callosum in healthy and first-break schizophrenic subjects
pp. 518-518(1)
Authors: Bagwell W.W.; Minshew N.; Rosenberg D.; Sweeney J.A.; Pettegrew J.W.; Keshavan M.S.

Cingulate cortex presynaptic proteins in schizophrenia
pp. 518-518(1)
Authors: Honer W.G.; Falkai P.; Young C.; Bonner J.; L. H.; Boulianne G.L.; Z. L.; Trimble W.S.

The corpus callosum in childhood onset schizophrenia
pp. 518-519(2)
Authors: Jacobsen L.K.; Giedd J.N.; Rajapakse J.C.; Hamburger S.D.; Vaituzis A.C.; Frazier J.A.; Lenane M.C.; Rapoport J.L.

Altered signal transduction in fibroblasts from first-episode schizophrenic patients
pp. 519-519(1)
Authors: Mahadik S.P.; Scheffer R.E.; Mukherjee S.; Correnti E.E.

Temporal lobe structure angulation in first-episode schizophrenia
pp. 519-519(1)
Authors: H. W.; Bilder R.M.; Lieberman J.A.

Brain CSF volume in patients with first-episode psychosis
pp. 519-519(1)
Authors: Hirayasu Y.; Shenton M.E.; Dickey C.C.; Salisbury D.F.; Fischer I.A.; Sherwood A.R.; Yurgelun-Todd D.A.; Tohen M.; McCarley R.W.

Baseline and follow-up mesiotemporal volumes in first episode schizophrenics
pp. 519-520(2)
Authors: Strous R.D.; Schenkler J.; Ashtari M.; Bilder R.M.; Lieberman J.A.

Atypical antipsychotic medication in the treatment of first episode schizophrenia
pp. 520-520(1)
Authors: Sheitrnan B.; Koreen A.; H. L.; Mendelovvitz A.; Alvir J.; Lieberman J.

Longitudinal neuropsychological change in first-episode schizophrenia
pp. 520-520(1)
Authors: Goldman R.S.; Bilder R.M.; Walder D.; Bates J.; Lieberman J.A.

Parkinsonism in drug-naive first-episode schizophrenic patients
pp. 520-521(2)
Authors: Scheffer R.E.; Correnti E.E.; Mukherjee S.

Incidence of suicide in a research study of first episode schizophrenia
pp. 521-521(1)
Authors: Mendelowitz A.; Lieberman J.; Koreen A.; Sheitman B.; Alvir J.; Becker J.

Suicidal ideation and behavior in recent-onset schizophrenia
pp. 521-521(1)
Authors: Young A.S.; Nuechterlein K.H.; Mintz J.; Ventura J.; Gitlin M.; Liberman R.P.

Self-injury: progress in the understanding of an intractable behavior
pp. 521-521(1)
Authors: Tuinier S.; Verhoeven W.M.A.

Persistent respiratory irregularity in patients with panic disorder
pp. 521-522(2)
Authors: Abelson J.L.; J. G.W.; Nesse R.M.; Curtis G.C.

Effect of paroxetine on heart rate variability in panic disorder: analysis of holter records
pp. 522-522(1)
Authors: Yeragani V.; Sobolewski E.; Johnson C.; Kay J.; Jampala V.C.; Hillman N.; Igel G.

Power spectrum of the QRS complex: comparison of patients with panic disorder and controls
pp. 522-522(1)
Authors: Yeragani V.; Berger R.; Songer D.; Yeragani S.

Seasonal variation of suicide in South Africa
pp. 522-523(2)
Authors: Flisher A.J.; Parry C.D.H.; Bradshaw D.; Juritz J.M.

The motor agitation and retardation scale: item analysis and inter-rater reliability
pp. 523-523(1)
Authors: Sobin C.; Mayer R.; Sackeim H.A.

Behavioral inhibition study of offspring of depressed and anxious adults
pp. 523-523(1)
Authors: Fairbanks J.M.; Klein R.G.

Latent structure of the Hamilton depression rating scale in major depressive disorder
pp. 523-524(2)
Authors: Cai J.; Galynker I.

Depressive personality characteristics and clinical depression
pp. 524-524(1)
Authors: Hartlage S.; Alloy L.B.; Fawcett J.; Arduino K.

Further development of a neural network for panic disorder
pp. 524-524(1)
Authors: Ownby R.L.; Carmin C.N.

Immune dysfunction in affective subtypes
pp. 524-524(1)
Authors: Hornig-Rohan M.; Goodman D.B.; Kamoun M.; Amsterdam J.D.

Are response inhibition failures in OCD related to abnormal fronto-striatal circuits?
pp. 524-525(2)
Authors: O'Hearn K.; Rosenberg D.; Dick E.; Sweeney J.

Evidence for a selective developmental neurocognitive deficit in pediatric OCD
pp. 525-525(1)
Authors: Rosenberg D.; Averbach D.; O'Hearn K.; Dick E.; Birmaher B.; Sweeney J.

Isolation-reared macaques are hyposensitive to stimuli in a two-bottle choice paradigm
pp. 525-525(1)
Authors: Paul I.A.; English J.A.; Ndebele K.; Wellons M.; Halaris A.

Diminished pulse-respiration-coupling in depressed patients
pp. 526-526(1)
Authors: Hoehn-Saric R.; Lehofer M.; Moser M.; Hildebrandt G.; Drnovsek B.; Niederl T.; Zapotoczky H.G.

Factors influencing cardiac vagal tone in depressed patients
pp. 526-526(1)
Authors: Hoehn-Saric R.; Moser M.; Lehofer M.; Egner S.; Voica M.; Messerschmidt D.; Zeiringer H.; Kenner T.

Biological ''markers'' in dysthymia
pp. 526-526(1)
Authors: Dunn E.J.; Coote M.; Browne G.; Steiner M.

Cholinergic hypersensitivity in intestinal allergy and depression
pp. 527-527(1)
Authors: Overstreet D.H.; Djuric V.J.; Bienenstock J.; Steiner M.; Perdue M.H.

Cortisol and maternal attraction to infant odor
pp. 527-527(1)
Authors: Steiner M.; Coote M.; Tran A.; Corter C.; Fleming A.

The Myers Briggs Type Indicator and psychiatric diagnosis
pp. 527-527(1)
Authors: Janowsky D.; Morter S.; Hong L.

Impact of a high intensity, easy access ambulatory program for bipolar disorder
pp. 527-528(2)
Authors: Bauer M.; McBride L.; Shea N.; Gavin C.; Holden F.; Kendall S.

Serotonin function and vulnerability to depression
pp. 528-528(1)
Authors: Miller H.L.; Damell A.; Cappiello A.; Bemman R.; Anand A.; Charney D.S.

Sibling resemblance for depression in a high-risk sample of adults
pp. 528-528(1)
Authors: Rende R.; Weissman M.

The relationship of prolactin to tardive dyskinesia and psychosis in treatment-resistant schizophrenia
pp. 528-528(1)
Authors: Verghese C.; Nair C.; Stanilla J.; Simpson G.

Differential effects of typical and atypical antipsychotic medication on plasma prolactin levels
pp. 529-529(1)
Authors: H. L.; Lieberman J.A.; Sheitman B.; Koreen A.R.; Kroenig M.; Mendelowitz A.; Umbricht D.; Alvir J.M.J.; Cooper T.

Predicting clinical response to clozapine treatment by plasma level
pp. 529-529(1)
Authors: Bera R.; Kalali A.H.; Gulasekaram B.; Hayes S.; Jin Y.; Costa J.; Oldroyd J.; Cooper T.; Potkin S.G.

The relationship between clozapine dose and plasma level and side effects
pp. 529-529(1)
Authors: Kalali A.H.; Bera R.; Gulasekaram B.; Hayes S.; Jin Y.; Costa J.; Oldroyd J.; Cooper T.; Potkin S.g.

Dose-related effects of clozapine on tardive dyskinesia among ''treatment-refractory'' patients with schizophrenia
pp. 529-530(2)
Authors: Nair C.; Abraham G.; de Leon J.; Stanilla J.K.; Josiassen R.C.; Simpson G.

Tardive dyskinesia, clozapine and treatment response
pp. 530-530(1)
Authors: Dalack G.W.; Becks L.; Baslock G.; Meador-Woodruff J.H.

Clozapine treatment of children and adolescents: a four year follow-up
pp. 530-530(1)
Authors: Kowatch R.A.; Gilfillan S.K.; Suppes T.; Fuentes R.M.

Clozapine treatment of childhood-onset schizophrenia
pp. 530-530(1)
Authors: Kumra S.; Jacobsen L.K.; Frazier J.A.; McKenna K.; Gordon C.T.; Smith A.K.; Rapoport J.L.

A one year randomized trial of clozapine vs. usual care in bipolar I patients
pp. 531-531(1)
Authors: Suppes T.; Rush A.J.; Webb A.; Carmody T.; Kraemer H.

RCBF changes with clozapine treatment in refractory bipolar disorder
pp. 531-531(1)
Authors: Trivedi M.H.; Suppes T.; Devous M.D.; Harris T.S.; Rush A.J.

Intermittent low dose clozapine sensitizes (kindles?) myoclonus
pp. 531-531(1)
Authors: Denney D.; Stevens J.R.; Szot P.

Agonist-induced internalization of the 5ht_2A receptor in vitro
pp. 531-532(2)
Authors: Berry S.A.; Khan N.; Roth B.L.

Regulation of platelet serotonin transporter by protein kinase C
pp. 532-532(1)
Authors: Marazziti D.; Mazzoni M.R.; Palego L.; Rotondo A.; Rossi A.; Lucacchini A.

Genetic approaches to elucidate serotonin_2A (5HT_2A) receptor function
pp. 532-532(1)
Authors: Toth M.; Sibille E.; Gyulai Z.; Gal J.

Cellular substrates for serotonergic modulation of gaba in the nucleus accumbens
pp. 532-532(1)
Authors: Van Bockstaele E.J.; Pickel V.M.

Rat dorsal raphe 5-HT_1B receptor MRNA is differentially regulated by fluoxetine and learned helplessness
pp. 533-533(1)
Authors: Neumaier J.F.; Petty F.; Szot P.; Kramer J.; Hamblin M.W.

Lumped constant for pharmacokinetic estimation of brain serotonin synthesis rates
pp. 533-533(1)
Authors: Shoaf S.E.; Schmall B.

5-HT_1A receptor sensitivity after 5-HT_2A receptor downregulation
pp. 533-533(1)
Authors: Hensler J.G.; Truett K.A.

Differential effects of typical and atypical antipsychotics on 5-HT release
pp. 533-534(2)
Authors: Kuroki T.; Ichikawa J.; Dai J.; Meltzer H.Y.

Ketanserin binding characteristics to 5-HT_2A receptor: evidence for two binding subsites
pp. 534-534(1)
Authors: Gurguis G.N.M.; Shewmake K.; Rush A.J.

Tryptophan depletion and behavioral disinhibition in male adolescents with aggressive, disruptive behavior
pp. 534-534(1)
Authors: LeMarquand D.G.; Benkelfat C.; Tremblay R.E.; Pihl R.O.; Young S.N.; Palmour R.M.

New indices of serotonin function and their relationship to impulsivity
pp. 534-534(1)
Authors: Reist C.; Albers L.; Bell K.; Tran D.; Helmeste D.; Tang S.W.

Self-reported abuse and biological measures in personality disorders
pp. 535-535(1)
Authors: New A.S.; Yehuda R.; Steinberg B.; Trestman R.L.; Mitropoulou V.; Coccaro E.F.; Siever L.J.

Serum cholesterol and impulsive aggressive behavior in personality disorder patients
pp. 535-535(1)
Authors: Zale C.; New A.S.; Trestman R.L.; Mitropoulou V.; Siever L.

Cerebrospinal fluid 5-HIAA is low in perpetrators of domestic violence
pp. 535-536(2)
Authors: George D.T.; Ragan P.W.; Rawlings R.; Umhau J.; Phillips M.; Shoaf S.; Linnoila M.

Cognitive impulsivity in adolescent conduct disorder and depression
pp. 536-536(1)
Authors: Pogge D.L.; Horan W.P.; Borgaro S.R.; Stokes J.M.; Lord J.J.; Harvey P.D.

Brain glucose metabolic rates in alcoholic patients
pp. 536-536(1)
Authors: Williams W.; Andreason P.; Ruttimann U.; Kerich M.; Rio D.; Rawlings R.; Brown G.; Hommer D.; Linnoila M.

Plasma fatty acids predict CSF 5-HIAA and HVA in normals, early and late onset alcoholics
pp. 536-536(1)
Authors: Hibbeln J.R.; Umhau J.C.; Salem N.; Rawlings R.; George D.T.; Linnoila M.

Conduct disorder, impulsivity, and substance abuse in adolescents
pp. 536-537(2)
Authors: Pogge D.L.; Borgaro S.R.; Horan W.P.; Stokes J.M.; Lord J.J.; Harvey P.D.

Acute fluoxetine enhances cocaine's action on brain reward
pp. 537-537(1)
Authors: J. C.; X. L.; Paredes W.; Gardner E.L.

Effects of d- and d,1-fenfluramine on emotions in males
pp. 537-537(1)
Authors: Berman M.; Coccaro E.F.; Kavoussi R.K.

Pain perception 1N self-injurious borderline patients
pp. 537-538(2)
Authors: Kemperman I.; Russ M.J.; Clark W.C.

Clonidine treatment of aggression in an autistic adult
pp. 538-538(1)
Authors: Villalba R.; Bauer M.S.

AP-2 activation of phenylethanolamine N-methyltransferase gene expression
pp. 538-538(1)
Authors: Wong D.L.; Ebert S.N.

5-HT_1A, MR and GR gene expression in the hippocampus of suicide victims
pp. 538-539(2)
Authors: Lopez J.F.; Little K.Y.; McLaughlin D.P.; Watson S.J.

AMPA subunit gene expression in the frontal cortices of schizophrenics
pp. 539-539(1)
Authors: Healy D.J.; Haroutunian V.; Powchik P.; Davis K.L.; Watson S.J.; Meador-Woodruff J.H.; Davidson M.

Evidence for linkage of bipolar disorder to HC 18 with a parent-of-origin effect
pp. 539-539(1)
Authors: Stine O.C.; J. X.; Koskela R.; McMahon F.J.; Gschwend M.; Friddle C.; Clark C.; McInnis M.G.; Simpson S.G.; Breschel T.; Vishio E.; Riskin K.; Feilotter H.; Chen E.; Shen S.; Folstein S.; Meyers D.A.; Botstein D.; Marr T.G.; DePaulo J.R.

Mood disorder phenotype in affected sib pairs sharing paternal alleles at D18S41
pp. 539-540(2)
Authors: McMahon F.J.; J.-F. X.; Simpson S.G.; McInnis M.G.; Stine O.C.; DePaulo J.R.

Genetic analysis of psychosis in Portuguese populations
pp. 540-540(1)
Authors: Pato C.N.; Pato M.T.; Kennedy J.; Azevedo M.H.

Gene variants and treatment response in depression and schizophrenia
pp. 540-540(1)
Authors: Ricketts M.H.; Amsterdam J.D.; Hornig-Rohan M.; Escobar J.I.; Singer J.; Ravichandran S.; Manowitz P.

Association of schizophrenia with VCFS and 22q11 deletions
pp. 540-540(1)
Authors: Morrow B.E.; Sirotkin H.; Goldberg R.; Carlson C.; Shprintzen R.; Kucherlapati R.

B37 trinucleotide repeats in schizophrenic patients and French and African controls
pp. 541-541(1)
Authors: Morris-Rosendahl D.J.; Burgert E.; Macher J.P.; Mayerova A.; Duval F.; Crocq M.A.

Study of HLA-DRB1 genotyping in schizophrenia in Japanese
pp. 541-541(1)
Authors: Sada M.; Horinouchi K.; Tsuji T.; Akimoto H.; Fujimoto T.; Takano T.; Takeuchi K.

Analysis of HLA-DRB1 alleles in alcoholism in Japanese
pp. 541-541(1)
Authors: Sada M.; Tsuji T.; Akimoto H.; Fujimoto T.; Uchida T.; Nakano T.

Autism and the X-chromosome: multipoint SIB pair analysis
pp. 541-542(2)
Authors: Hallmayer J.; Hebert J.; Spiker D.; Lotspeich L.; McMahon W.M.; Petersen P.B.; Nicholas P.; Pingree C.; Lin A.; Risch N.; Cavalli-Sforza L.; Ciaranello R.D.

Genetic study of a murine model for opioid addiction
pp. 542-542(1)
Authors: Berrettini W.; Vuoristo J.; Ferraro T.; Ala-Kokko L.; Alexander R.; Hoehe M.; Buchberg A.; Vogel W.; Prockop D.

Targeted disruption of the mouse RPX gene
pp. 542-542(1)
Authors: Feltner D.E.; Hermesz E.; Grinberg A.; Mahon K.A.

Domains of psychopathology: is schizophrenia different from other psychoses?
pp. 542-542(1)
Authors: Ratkonda S.S.; Amador X.F.; Gorman J.M.

The effects of clozapine on symptom clusters in older ''treatment-refractory'' patients
pp. 543-543(1)
Authors: Abraham G.; Tracy J.I.; Nair C.; Josiassen R.C.; Simpson G.

Associated psychiatric syndromes in chronic schizophrenia
pp. 543-543(1)
Authors: Bermanzohn P.C.; Siris S.G.; Porto L.

Overlap of negative and depressive symptoms in non-schizophrenic subjects
pp. 543-543(1)
Authors: Galynker I.; Cai J.; Salvit C.; Miner C.; Rosenthal R.

Schizophrenic symptoms and specific regions of prefrontal cortex
pp. 543-544(2)
Authors: Wible C.G.; Shenton M.E.; Kikinis R.; Jolesz F.; McCarley R.W.

Positive symptoms in dopamincrgic psychosis--implications for the dopamine hypothesis of schizophrenia
pp. 544-544(1)
Authors: Heinz A.; Knable M.B.; Pietzcker A.; Schmidt L.G.; Weinberger D.R.

Schizophrenia, borna disease, and neurological signs in a monozygotic twin study cohort
pp. 544-544(1)
Authors: Waltrip R.W.; Torrey E.F.; King L.R.; Weinberger D.R.; Rickler K.C.; Rubin S.A.; Carbone K.M.

Auditory hallucinations: relationship to diagnosis & severity of illness characteristics
pp. 544-545(2)
Authors: Elliott A.J.; Roy-Byrne P.; Tucker G.

Current models of schizophrenia: explanatory potential
pp. 545-545(1)
Authors: LoboPrabhu S.; Tandon R.; Jibson M.; Taylor S.F.

Negative symptoms improve in deficit and nondeficit schizophrenia
pp. 545-545(1)
Authors: Tandon R.; Karam-Hage M.; Goldman M.; Jibson M.; DeQuardo J.R.; Taylor S.F.; Decker L.

One-year outcome in deficit and nondeficit schizophrenia
pp. 545-545(1)
Authors: Goldman M.; Tandon R.; Jibson M.; DeQuardo J.R.; Taylor S.F.; Decker L.; Goodson J.

Premorbid dysfunction in schizophrenia: nature and progression
pp. 546-546(1)
Authors: Gribbin D.; Tandon R.; DeQuardo J.R.; Goldman M.; McGrath M.; Wilson R.; Smet I.C.

Neurological soft signs, negative symptoms, and flat affect
pp. 546-546(1)
Authors: Smith R.C.; Kadewari R.P.; Dickson S.P.; Karim R.; Pouget E.; Alpert M.

The association of cognitive performance with quality of life in schizophrenia
pp. 546-546(1)
Authors: Swanson C.L.; Gur R.C.; Petty R.G.; Gur R.E.

Validity of the CGI as a severity measure in schizophrenia
pp. 546-547(2)
Authors: Goldman M.; Tandon R.; DeQuardo J.R.; Jibson M.; Taylor S.F.

Cigarette smoking and psychiatric illness: a VA outpatient survey
pp. 547-547(1)
Authors: Dalack G.W.; Becks L.; Castine M.; Pomerleau C.; Meador-Woodruff J.H.

Nicotine withdrawal and psychiatric symptoms in smokers with schizophrenia
pp. 547-547(1)
Authors: Dalack G.W.; Becks L.; Hill E.; Pomerleau O.; Meador-Woodruff J.H.

Test-retest stability of the neurologic examination in schizophrenia
pp. 548-548(1)
Authors: Sanders R.D.; Forman S.D.; Keshavan M.S.; Ganguli R.; van Kammen D.P.

Portable device for quantitative measurement of motor symptoms
pp. 548-548(1)
Authors: K. O.L.; Heit G.; Sullivan E.V.; Wasserstein P.; Silverberg G.

Instrumental assessment of longitudinal variations in tardive dyskinesia
pp. 548-548(1)
Authors: Stanilla J.K.; Buchel C.; Alarcon J.; de Leon J.; Simpson G.M.

Thought disorder index (TDI) in schizotypal personality disorder
pp. 549-549(1)
Authors: Voglmaier M.M.; Shenton M.E.; McCarley R.W.; Seidman L.J.; Salisbury D.; Sollinger J.

Disturbed thought and information processing deficits in schizophrenia
pp. 549-549(1)
Authors: Perry W.; Braff D.

Age-related changes in formal thought disorder in chronic schizophrenic patients
pp. 549-549(1)
Authors: Lombardi J.; Harvey P.D.; Leibman M.; Parrella M.; White L.; Powchik P.; Mohs R.; Davidson M.; Davis K.

Understanding delusions in schizophrenia using visual scan paths
pp. 549-550(2)
Authors: Phillips M.L.; David A.S.

Increased genetic liability to schizophrenia-spectrum disorders in first degree relatives of neuroleptic-resistant schizophrenic patients
pp. 550-550(1)
Authors: Joober R.; Benkelfat C.; Lal S.; Bloom D.; Fortin D.; Lalonde P.; Palmour R.; Rouleau G.

Familial and sporadic schizophrenia show distinct neurobiology
pp. 550-550(1)
Authors: Malaspina D.; Gorman J.; Bruder J.; Amador X.; Goetz R.; Friedman J.H.; Kaufmann C.

Factor structure of schizotypy in relatives of schizophrenia patients
pp. 550-550(1)
Authors: Bergman A.; Silverman J.; Smith C.; Siever L.; Mohs R.; Davis K.

Schizophrenia and affective disorders after prenatal famine
pp. 551-551(1)
Authors: Brown A.S.; Susser E.S.; Hoek H.W.; Neugebauer R.; Lin S.P.; Gorman J.M.

The effect of neuroleptic drugs on olfactory sensitivity in schizophrenia
pp. 551-551(1)
Authors: Sirota P.; Ben-David I.; Luca-Haimovici K.; Zohar J.; Gross-Isseroff R.

An analysis of olfactory deficits in schizophrenia
pp. 551-551(1)
Authors: Serby M.; Kalkstein D.; Aryan M.; Schmeidler J.

Substance abuse and the course of schizophrenia
pp. 551-552(2)
Authors: Turner W.M.; M. T.T.

Learning social skills in psychotic patients: gender effects
pp. 552-552(1)
Authors: Smith T.E.; Hull J.W.; Goodman M.; Anthony D.T.; Kentros M.K.

Polysomnographic abnormalities in schizophrenia: a replication
pp. 552-552(1)
Authors: Maixner S.; Tandon R.; Douglass A.; Shipley J.E.; Decker L.; Goldman M.

Hypercortisolemia and cognitive dysfunction in schizophrenia
pp. 552-552(1)
Authors: G. H.; Tandon R.; Goldman R.; Smet I.C.; Taylor S.F.; DeQuardo J.R.; Goldman M.

Age of illness onset and the inpatient drug washout
pp. 553-553(1)
Authors: Sharma R.P.; Dowd S.; Davis J.M.; Janicak P.G.

Respiratory sinus arrhythmia in schizophrenia and mania
pp. 553-553(1)
Authors: Smith S.; Schnur D.B.; Yehuda R.; Siddiqui F.

Probable neuroleptic induced tardive dyskinesia in association with combined fluoxetine and risperidone treatment
pp. 553-553(1)
Authors: Daniel D.G.; Egan M.; Hyde T.

Neuroleptic effects on the respiratory chain
pp. 553-553(1)
Authors: Higgins D.S.; Garcia-Osuna M.; Greenamyre J.T.

CBF activation in post traumatic stress disorder: spect studies
pp. 553-554(2)
Authors: Liberzon I.; Fig L.M.; Taylor S.F.; Jung T.D.; Minoshima S.; Koeppe R.A.

Co-morbidity of attention deficit disorder in adult patients screened for PTSD
pp. 554-554(1)
Authors: Adler L.A.; Resnick S.; Rotrosen J.

Is post stress HPA response prolonged (disinhibited) in aged humans?
pp. 554-554(1)
Authors: Stokes P.E.; Mourilhe P.R.; Barsdorf A.I.; Ombid H.

The prevalence of PTSD among car accident victims; a prospective study
pp. 554-555(2)
Authors: Klein E.; Arnon I.; Snau N.; Lavie P.

Long term behavioral and neurochemical changes after isolation rearing in rats
pp. 555-555(1)
Authors: Bakshi V.P.; Schwarzkopf S.B.; Braff D.L.; Geyer M.A.

The startle reflex is facilitated by darkness in humans
pp. 555-555(1)
Authors: Grillon C.; Pellowski M.; Merikangas K.

Fear-potentiated startle in vietnam veterans with PTSD
pp. 555-556(2)
Authors: Grillon C.; Morgan C.A.

Factor analysis of the dissociative experiences scale in PTSD
pp. 556-556(1)
Authors: Amdur R.; Casada J.H.; Liberzon I.

Behavioral studies in neurodevelopment
pp. 556-556(1)
Author: Walker E.F.

Decreased caudate volume in first episode schizophrenia
pp. 556-557(2)
Authors: Keshavan M.S.; Kisler T.; Rosenberg D.; Bagwell W.; Sweeney J.; Haas G.; Schooler N.; Pettegrew J.

Organization and development of the embryonic forebrain
pp. 557-557(1)
Author: Rubenstein J.L.R.

Development of limbic cortex and circuits
pp. 557-557(1)
Author: Levitt P.

Developmental abnormalities of the prefrontal cortex in schizophrenia
pp. 557-557(1)
Authors: Akbarian S.; Jones E.G.

Neuroleptics as antagonists and agonists of neurotransmitter receptors
pp. 557-558(2)
Authors: Richelson E.; Zeng X.P.; Le F.

Roles of metabotropic glutamate receptors in the hippocampus
pp. 558-558(1)
Author: Conn P.J.

Adaptation of NMDA receptors following antidepressant treatments
pp. 558-558(1)
Author: Skolnick P.

A role for CREB and BDNF in the actions of antidepressants
pp. 558-559(2)
Author: Duman R.S.

Resonance and positron emission tomography
pp. 559-559(1)
Authors: Andreasen N.C.; Swayze V.; O'Leary D.S.; Nopoulos P.; Cizadlo T.; Harris G.; Arndt S.; Flaum M.

Magnetic resonance imaging in schizophrenia
pp. 559-559(1)
Authors: Yurgelun-Todd D.A.; Sherwood A.R.; Kinney D.; Renshaw P.F.

Using MRI and MRS to investigate gray matter deficits in schizophrenia
pp. 559-559(1)
Author: K. O.L.

Increased striatal dopamine release in drug free schizophrenic subjects
pp. 560-560(1)
Authors: Laruelle M.; Abi-Dargham A.; van Dyck C.H.; Krystal J.H.; Charney D.S.; Innis R.B.

Pet findings in differential OCD treatment response
pp. 560-560(1)
Authors: Baxter L.R.; Brody A.L.; Saxena S.; Ackermann R.F.; Schwartz J.M.; Colgan M.

MRS: at the edge of pharmacotherapeutics?
pp. 560-560(1)
Authors: Karson C.N.; Heimberg C.; Komoroski R.; Omori M.

Monoamines, personality, and early-onset alcoholism
pp. 560-561(2)
Author: Cloninger C.R.

Molecular genetics of impaired impulse control and early onset alcoholism
pp. 561-561(1)
Authors: Goldman D.; Nielsen D.; Okada M.; Adamson M.; Lappalainen J.; Malhotra N.; Pesonen U.; Koulu M.; Eggert M.; Virkkunen M.; Ozaki N.; Linnoila M.

A nonhuman primate model of type II excessive alcohol consumption
pp. 561-561(1)
Authors: Higley J.D.; Mehlman P.; Suomi S.J.; Linnoila M.

Clinical, neuroendocrine and treatment studies of impulsive aggression
pp. 561-561(1)
Author: Coccaro E.F.

Two homologous genes associated with early onset familial Alzheimer's disease
pp. 562-562(1)
Authors: St. George-Hyslop P.; Rogaev E.I.; Sherrington R.; Rogaeva E.A.; Rogaeva G.; Levesque G.; Ikeda M.; Y. L.; H. C.; C. L.; Holman K.; Fraser P.E.; Rommens J.M.

The effect of amyloid precursor protein and presenilin mutations on amyloid beta protein
pp. 562-562(1)
Authors: Younkin S.G.; X. H.S.; Scheuner D.; Eckman C.; Prada C.-M.; Jensen J.; Lannfelt L.; Hardy J.; Tanzi R.; Schellenberg G.; Selkoe D.; Suzuki N.

Apolipoprotein is a susceptibility genetic locus that affects the expression of late-onset familial and sporadic Alzheimer's disease
pp. 562-562(1)
Authors: Roses A.D.; Saunders A.M.; Pericak-Vance M.A.; Einstein G.; Hulette C.; Schmechel D.E.; D. H.; Strittmatter W.J.

Anti-inflammatory drug studies in Alzheimer's disease
pp. 563-563(1)
Authors: Aisen P.S.; Marin D.; Davis K.L.

Biological aspects of misperceptions
pp. 563-563(1)
Author: Ciprian-Ollivier J.

Recent biological research trends in the institute of mental health of BMU
pp. 563-563(1)
Author: Y.-C. S.

Putative endogenous anxiogens and anxiolytics
pp. 563-564(2)
Author: Lapin I.P.

D4DR exon III polymorphism association with personality variation in normals
pp. 564-564(1)
Authors: Ebstein R.P.; Osher Y.; Belmaker R.H.

Molecular genetic studies in affective disorders
pp. 564-564(1)
Author: Mendlewicz J.

D2 - Receptor imaging (SPECT) as a tool for measuring the efficacy and side-effect profile of treatment with neuroleptics
pp. 564-564(1)
Authors: Kasper S.; Tauscher J.; Kufferle B.; Heiden A.; Neumeister A.; Barnas C.; Asenbaum S.; Podreka I.; Brucke T.

P300 latency and cortical tissue volume in alcoholics
pp. 565-565(1)
Authors: Ford J.M.; Mathalon D.H.; Rosenbloon M.J.; Lim K.O.; Pfefferbaum A.

ERP correlates of recognition memory: abnormalities in schizophrenia
pp. 565-565(1)
Authors: Turetsky B.; Colbath E.A.; Moberg P.; Mozely L.H.; Gur R.C.; Gur R.E.

ERP and behavioral indices of working memory dysfunction in schizophrenia
pp. 565-565(1)
Authors: Javitt D.C.; Shelley A.-M.; Leiderman E.; March L.; Cowan N.; Ritter W.

Topographic analyses of brain potentials in depressed patients
pp. 566-566(1)
Authors: Bruder G.; Tenke C.; Towey J.; Leite P.; Fong R.; Stewart J.; Quitkin F.

Asymmetric current density as depressives evaluate life events
pp. 566-566(1)
Authors: Luu P.; Tucker D.M.; McDougal L.

Auditory and visual high density ERP studies in schizophrenia
pp. 566-566(1)
Authors: Potts G.F.; O'Donnell B.; Shenton M.E.; Allard J.; McCarley R.W.

Antisense ''knockdown'' of CRH₁-but not of CRH₂- receptors is anxiolytic in rats
pp. 566-567(2)
Authors: Montkowski A.; Skutella T.; Liebsch G.; Behl C.; Landgraf R.; Holsboer F.

Stress - restress: an animal model of HPA abnormalities in PTSD
pp. 567-567(1)
Authors: Liberzon I.; Krstov M.; Young E.A.

Panic disorder is unlikely to be a homogeneous autosomal dominant disorder: results of a genome-wide genetic screen
pp. 567-567(1)
Authors: Knowles J.A.; Vieland V.J.; Weissman M.M.; Heiman G.; de Jesus G.; Judenberg A.; Cunjak J.; Mick S.; Adams P.; Hodge S.E.; Klein D.F.; Fyer A.J.; Gilliam T.C.

A trait marker for panic disorder
pp. 567-567(1)
Author: Coryell W.H.

A controlled trial of fluvoxamine for OCD in children and adolescents
pp. 568-568(1)
Authors: Riddle M.A.; Claghorn J.; Gaffney G.; Greist J.H.; Holland D.; Landbloom R.; McConville B.; Pigott T.; Pravetz M.; Walkup J.T.; Yaryura-Tobias J.; Houser V.P.

Beyond efficacy: treatment outcome in panic disorder
pp. 568-568(1)
Authors: Mavissakalian M.; Perel J.; Talbott-Green M.; Sloan C.

A neural network model of stroop interference and facilitation effects in schizophrenia
pp. 568-568(1)
Authors: Cohen J.D.; Usher M.

Stroop performance in first degree relatives of schizophrenic patients
pp. 568-569(2)
Authors: Yurgelun-Todd D.A.; Gruber S.A.; Baird A.A.

Dissociating selective attention and stress in the stroop interference paradigm
pp. 569-569(1)
Authors: Taylor S.F.; Kornblum S.; Koeppe R.A.

Working memory as a factor in language dysfunction in schizophrenia
pp. 569-569(1)
Authors: Niznikiewicz M.A.; Nestor P.G.; O'Donnell B.F.; Allard J.E.; Shenton M.E.; McCarley R.W.

Working and strategic memory changes in schizophrenia
pp. 569-570(2)
Authors: Singh J.; Gopal K.; Yohanna D.

Verbal learning and memory in schizotypal personality disorder
pp. 570-570(1)
Authors: Bergman A.; Harvey P.; Roitman S.; Mitropoulou V.; Marder D.; Siever L.

Schizophrenic spatial working memory: neuropsychological correlates
pp. 570-570(1)
Authors: Levitt J.J.; Nestor P.G.; Allard J.E.; Karapelou M.E.; O'Donnell B.F.; McCarley R.W.

Improvement in working memory in schizotypal subjects following physostigmine
pp. 570-570(1)
Authors: Callahan A.M.; New A.S.; Bergman A.; Mitropoulou V.; Cornblatt B.; Siever L.J.

The effects of risperidone vs. haloperidol on spatial working memory in treatment-resistant schizophrema
pp. 571-571(1)
Authors: McGurk S.R.; Green M.F.; Wirshing W.C.; Ames D.; Marshall B.D.; Marder S.R.

Rolipram, a phosphodiesterase inhibitor, facilitates late phase LTP and improves memory
pp. 571-571(1)
Authors: Barad M.; Bourtchuladze R.; Golan H.; Bach M.E.; Zhuo M.; Hawkins R.; Kandel E.

The influence of ECT on olfactory memory
pp. 571-571(1)
Authors: Sirota P.; Mosheva T.

Olfactory functioning in siblings discordant for schizophrenia
pp. 571-572(2)
Authors: Moberg P.J.; Doty R.L.; Turetsky B.I.; Wylonis L.; Cannon T.D.; Acosta T.A.; Gur R.E.

Working memory and olfactory identification in schizotypal personality
pp. 572-572(1)
Authors: Park S.; McTigue K.; Schoppe S.; Laciak M.; Raine A.

Olfactory sensitivity in eating disorders
pp. 572-572(1)
Authors: Sirota P.; Shamir D.; Mitrany E.

Attentional and eye movement dysfunctions in schizophrenia
pp. 572-572(1)
Authors: Obuchowski M.; Chan T.; Sweeney J.A.; Schnur D.B.; O'Brien J.; Cornblatt B.A.

Predictive and visually-guided saccades in obsessive-compulsive disorder
pp. 573-573(1)
Authors: Farber R.H.; Clementz B.A.; Lam M.N.; Swerdlow N.R.

The effects of distracter stimuli upon saccade latency in schizophrenics
pp. 573-573(1)
Authors: Schwartz B.D.; Evans W.J.; O'Brien B.; Fogarty M.; Winstead D.K.

Neural substrates of eye tracking deficits in relatives of schizophrenics
pp. 573-573(1)
Authors: O'Driscoll G.A.; Benkelfat C.; Joober R.; Lal S.; Evans A.C.

Oculomotor. Cognitive and subjective effects of ketamine in normals
pp. 574-574(1)
Authors: Roy-Byrne P.; Radant A.; Bowdle A.; Kharasch E.; Cowley D.

Smooth pursuit eye movements after smoking in schizophrenic patients
pp. 574-574(1)
Authors: Olincy A.; Ross R.G.; Young D.A.; Roath M.; Freedman R.

Sex differences in olfactory identification & WCST performance in schizophrenia
pp. 574-574(1)
Authors: Seidman L.J.; Goldstein J.M.; Goodman J.M.; Koren D.; Turner W.; Tsuang M.T.

The impact of sex on cognition and structural brain MRI in schizophrenia
pp. 575-575(1)
Authors: Goldstein J.M.; Seidman L.J.; Goodman J.M.; Koren D.; Makris N.; Kennedy D.N.; Weintraub S.; Caviness V.S.; Tsuang M.T.

Time estimation in schizophrenia
pp. 575-575(1)
Authors: Tracy J.I.; Monaco C.A.; Chambliss C.; McMichael H.; Tyson K.

Disordered time perception following unilateral amobarbital injection
pp. 575-575(1)
Authors: Drane D.L.; Lee G.P.; Loring D.W.; Meador K.J.

Determinants of category and phonemic fluency deficits in chronic schizophrenics
pp. 575-576(2)
Authors: Harvey P.D.; Lombardi J.; White L.; Parrella M.; Powchik P.; Mohs R.; Davidson M.

Methylphenidate effects on verbal fluency in schizophrenia
pp. 576-576(1)
Authors: Szeszko P.R.; Bilder R.M.; Walder D.J.; Lieberman J.A.

Abnormal categorical perception of simple speech sounds in schizophrenia
pp. 576-576(1)
Authors: Cienfiuegos A.; March L.; Shelley A.M.; Javitt D.C.

Verbal learning and organization in schizotypal personality disorder
pp. 576-577(2)
Authors: Voglmaier M.M.; Seidman L.J.; Salisbury D.; McCarley R.W.; Sollinger J.

Clinical correlates of perceptual organization dysfunction in schizophrenia
pp. 577-577(1)
Authors: Silverstein S.M.; Schwarzkopf S.B.; Light G.; Matteson S.; O'Connor B.; Schenkel L.; Pucher K.; Hems L.

Visuospatial working memory in schizotypal personality disorder
pp. 577-577(1)
Authors: Roitman S.E.L.; Keefe R.S.E.; Dupre R.L.; Siever L.J.

Transient versus sustained visual channels in the VBM deficits of schizophrenia
pp. 577-577(1)
Authors: Cadenhead K.S.; Braff D.L.

Recognition of facial expression and emotional prosody in schizophrenia
pp. 578-578(1)
Authors: Shaw R.J.; Ringo D.L.; Dong M.; Lim K.O.

Gender and neuropsychological function in schizophrenia
pp. 578-578(1)
Authors: Smet I.C.; Tandon R.; Goldman R.S.; Decker L.; Lelli G.; Berent S.

Neuropsychological measures of prefrontal dysfunction in schizophrenia
pp. 578-578(1)
Authors: Seidman L.J.; Oscar-Berman M.; Kalinowski A.G.; Ajilore O.; Kremen W.S.; Faraone S.V.; Tsuang M.T.

Neuropsychological probes of prefrontal dysfunction in schizophrenia
pp. 578-579(2)
Authors: Kremen W.S.; Seidman L.J.; Oscar-Berman M.; Shore A.R.; Faraone S.V.; Tsuang M.T.

Chronicity and neuropsychological dysfunction in schizophrenia
pp. 579-579(1)
Authors: Smet I.C.; Tandon R.; Goldman R.S.; Decker L.; Lelli G.; Berent S.

Neuropsychological correlates of prefrontal volume in schizophrenia
pp. 579-579(1)
Authors: Lencz T.; Bilder R.M.; Bogerts B.; Ashtari M.; H. W.; Alvir J.M.; Schenkler J.; Lieberman J.A.

Mechanisms of selective attention in schizophrenia
pp. 579-580(2)
Authors: Barch D.M.; Carter C.S.; Hachten P.C.

Disturbances of auditory localization and trajectory discrimination in schizophrenia
pp. 580-580(1)
Authors: Greene R.W.; O'Donnell B.F.; Allaban Y.A.; Stylianopoulos K.C.; Allard J.E.

Computer modeling of adaptive depression and asymmetric hemispheric processing
pp. 580-580(1)
Author: Webster C.

Cognitive impairment in euthymic patients with bipolar affective disorder
pp. 580-580(1)
Authors: van Gorp W.G.; Altshuler L.L.; Dixon W.; Theberge D.C.

Clinical and neuropsychological deficits in bipolar and schizophrenic patients
pp. 580-581(2)
Authors: Smith A.; McKay D.; Schnur D.; Smith S.; Obuchowski M.; Osgood G.; Cornblatt B.

Orienting response in schizophrenia and mania: neuropsychological testing
pp. 581-581(1)
Authors: Schnur D.B.; Smith S.; Smith A.; McKay D.; Obuchowski M.; Stewart A.; Win P.

Effects of amphetamine on cognitive impairment in schizotypal personality disorder
pp. 581-581(1)
Authors: Kirrane R.; Trestman R.; Mitropoulou V.; Cornblatt B.; Siever L.

Kinase-dependent spontaneous activity of G protein-coupled receptors
pp. 581-582(2)
Authors: Deth R.C.; Zhu Q.B.; Teeter M.M.; DuRand C.J.

Apoptosis in the rat dentate gyrus: the effect of aging, stimulation by dexamethasone, and the apparent protective role of corticosterone
pp. 582-582(1)
Authors: Hassan A.H.S.; Patchev V.K.; Almeida O.F.X.; Holsboer F.

Cytokine regulation of apoptosis in fetal substantia nigra cultures
pp. 582-582(1)
Authors: Jarskog L.F.; Gilmore J.H.

HPLC determination of agmatine in rat brain and human plasma
pp. 582-583(2)
Authors: Halaris A.E.; Feng Y.-Z.; Piletz J.E.

Differential activation of zif268 in the amygdala in response to mCPP
pp. 583-583(1)
Authors: Altemus M.; Paletzki R.; Gerfen C.R.; Murphy D.L.

Antibodies to human heat shock protein in patients with schizophrenia and major depression
pp. 583-583(1)
Authors: Sirota P.; Mazeh D.; Novogrotsky A.

Effects of intra-accumbens neurotensin on sensorimotor gating
pp. 583-583(1)
Authors: Feifel D.; Frillman K.; Dulawa S.; Swerdlow N.R.

Decreased [³H]cAMP binding in postmortem brain in bipolar disorder
pp. 583-584(2)
Authors: Rahman S.; Li P.P.; Kish S.J.; Young L.T.; Warsh J.J.

Elevated intracellular calcium in transformed lymphoblasts in bipolar I disorder
pp. 584-584(1)
Authors: Kamble 1 A.; Emamghoreishi M.; Schlicter L.; Li P.; Parikh S.; Sen J.; Warsh J.J.

Nocturnal oxytocin secretion is reduced in major depression
pp. 584-584(1)
Authors: Zetzsche T.; Frasch A.; Jirikowski G.; Murck H.; Steiger A.

Uncoupling of CNS serotonin and norepinephrine systems in depression
pp. 584-585(2)
Authors: Geracioti T.D.; Loosen P.; Ekhator N.; Schmidt D.; Baker D.; Richtand N.; Kascow J.; Keck P.; Ebert M.

Steroid effects on cell membrane structure: implications for depressive illness
pp. 585-585(1)
Authors: Mason R.P.; Golden G.A.; Mason P.E.; Rubin R.T.

Amesergide pre-treatment of m-CPP in normal controls
pp. 585-585(1)
Authors: Wong C.M.; Hollander E.; Decaria C.

Expression of MEF2C by subsets of neocortical and hippocampal neurons
pp. 585-586(2)
Authors: Li Y.L.; Leifer D.

Effects of typical and atypical antipsychotics on AMPA site binding
pp. 586-586(1)
Authors: McCoy L.; Richfield E.K.

NMDA receptor function and schizophrenia: studies with ketamine
pp. 586-586(1)
Authors: Malhotra A.K.; Pinals D.A.; Weisenfeld N.; Pickar D.; Breier A.

In vitro agonists reverse neuroleptic induced decline in PCP site binding
pp. 586-586(1)
Authors: McCoy L.; Richfield E.K.

Brain noradrenergic receptors in major depression and schizophrenia
pp. 587-587(1)
Authors: Ordway G.A.; Rajkowska G.; Luker S.N.; Dilley G.; Meltzer H.Y.; Overholser J.; Stockmeier C.A.

Differential regulation of non-NMDA subunit mRNA by antipsychotics in rat
pp. 587-587(1)
Authors: Healy D.J.; King R.E.; Bovenkerk K.A.; Damask S.P.; Meador-Woodruff J.H.

Neurotensin and metabolites in CSF of patients with schizophrenia and controls
pp. 587-587(1)
Authors: Butler P.D.; Printz D.J.; DeSanti L.; Issa F.; Gorman J.M.; Carraway R.E.

Defective utilization of precursor essential fatty acids in schizophrenia
pp. 588-588(1)
Authors: Mahadik S.P.; Shendarkar N.S.; Scheffer R.E.; Mukherjee S.; Correnti E.E.

Elevated plasma lipid peroxides in schizophrenic patients without dementia
pp. 588-588(1)
Authors: Evans D.R.; Puczkowski P.Y.; Brandsma M.J.; Mahadik J.S.; Mahadik S.P.

Metrifonate, physostigmine and tacrine: effects on the processing of APP
pp. 588-588(1)
Authors: Lahiri D.K.; Nall C.; Farlow M.R.

Expression of beta-amyloid precursor protein in the developing rat brain
pp. 589-589(1)
Authors: Lahiri D.K.; Nall C.; Zaphiriou M.; Nurnberger J.I.; Nurnberger J.I.

Effect of chronic stress and antidepressants in rat hippocampal function
pp. 589-589(1)
Authors: Zimmer C.A.; Lopez J.F.; Campeau S.; Watson S.J.

Atropine reduces neuronal activity in cortical, but not subcortical regions of rat brain
pp. 589-589(1)
Authors: Hammer R.P.; Jacobson S.A.; Foran S.; Cooke E.S.

Atropine selectively reduces metabolic activity in rat cerebral cortex
pp. 590-590(1)
Authors: Jacobson S.A.; Thomas W.L.; Cooke E.S.; Berezovskaya A.; Hammer R.P.

Haloperidol attenuates CRF release in the rat: a microdialysis study
pp. 590-590(1)
Authors: Forman S.D.; van Kammen D.P.

Hormone stimulation of catecholamine innervation in primate prefrontal cortex
pp. 590-590(1)
Author: Kritzer M.F.

Amphetamine psychosis in male and female rhesus monkeys
pp. 590-591(2)
Authors: Castner S.A.; Goldman-Rakic P.S.

Cytochrome P450-26 (CYP2D6) genotype: relationship with clozapine and haloperidol metabolism.
pp. 591-591(1)
Authors: de Leon J.; Wedlund P.; Ehlers R.; Josiassen R.; Cooper T.; Simpson G.

Magnesium sulphate has GABA-agonistic effects on sleep in healthy men
pp. 591-591(1)
Authors: Murck H.; Holsboer F.; Steiger A.

Cholinesterase inhibitor alters escape/reversal in ach-sensitive rats
pp. 591-592(2)
Authors: Lyon M.; Karson C.N.

The effect of catecholamine depletion on thyrotropin secretion
pp. 592-592(1)
Authors: Krahn L.E.; Zimmermann R.C.; Klee G.G.; Lin S.C.; Sauer M.V.

High voltage-activated calcium channels: review and implications for mental illness
pp. 592-592(1)
Authors: Black J.L.; Lennon V.A.

Abnormal peripheral benzodiazepine receptors in social phobia
pp. 592-592(1)
Authors: Johnson M.R.; Lydiard R.B.; Diamond B.I.; Marazziti D.

Fluoxetine treatment selectively causes brain accumulation of allopregnanolone (ALLO)
pp. 592-593(2)
Authors: Guidotti A.; Uzunov D.P.; Costa E.

A potential novel binding site for MAO inhibitors in brain
pp. 593-593(1)
Authors: Levant B.; Moehlenkamp J.D.; Morgan K.A.

Reproducibility of plasma catecholamine metabolites in normal subjects
pp. 593-593(1)
Authors: Hashmi A.; Amin F.; Knott P.J.

Oxytocin effects on AMPA receptor mRNA regulation in hippocampus
pp. 593-594(2)
Authors: Karam- Hage M.; Liberzon I.; Bovenkerk K.A.; Young E.A.; Meador-Woodruff J.H.

Gender differences in noradrenergic and serotonergic studies
pp. 594-594(1)
Authors: A. M.W.-M.; New A.S.; Mitropoulou V.; Trestman R.L.; Coccaro E.F.; Siever L.J.

Synapsin isoforms from primitive vertebrates: evolutionary and functional significance
pp. 594-594(1)
Authors: H.-T. K.; Stefani G.; H.-Q. H.; Pieribone V.A.; Greengard P.

Lithium and carbamazepine differentially affect locomotion and camp binding stimulated by cholera toxin
pp. 594-595(2)
Authors: Kofman O.; Rahman S.; P. P.L.; Warsh J.J.

Decreased level of N-acetylaspartate in basal ganglia of patients with alcoholism
pp. 595-595(1)
Authors: Yamagochi H.; Kuroda K.; Motooka T.; Nakazawa Y.; Tsuji T.; Akimoto H.; Uchida T.; Fujimoto T.; Nakano T.

Migraine and the contents of tyramine and phenylethylamine in food
pp. 595-595(1)
Authors: Mosnaim A.D.; Freitag F.; Karoum F.; Wolf M.E.; Diamond S.; Salas M.A.

GABA-serotonin interactions in healthy subjects: implications for psychosis
pp. 595-596(2)
Authors: Gil R.; C.D'Souza D.; Zuzarte E.; Damon D.; Genovese A.; Boutros N.; Abi-Dargham A.; Innis R.; Charney D.; Krystal J.

CSF neuropeptide dysregulation in patients with affective disorder
pp. 596-596(1)
Authors: Frye M.A.; Gary K.A.; George M.S.; Cora-Locatelli G.; Huggins T.; Pazzaglia P.J.; Callahan A.M.; Davis C.; Marangell L.; Rubinow D.; Winokur A.; Post R.M.; Mathe A.A.

Problems in post-mortem diagnosis can be solved
pp. 596-596(1)
Authors: Bigelow L.B.; Torrey E.F.; Kleinman J.E.

Antipsychotic drug dosing
pp. 596-597(2)
Authors: Davis J.M.; Janicak P.; Sharma R.

Does serotonin blockade alter antipsychotic drug response?
pp. 597-597(1)
Authors: Davis J.M.; Janicak P.; Sharma R.

Treatment of schizophrenia: new antidopaminergic strategies
pp. 597-597(1)
Authors: Lahti A.C.; Weiler M.A.; Corey P.K.; Warfel D.T.; Lahti R.A.; Carlsson A.; Tamminga C.A.

Efficacy and safety of three doses of sertindole and haloperidol in schizophrenic patients
pp. 597-597(1)
Authors: Bark N.; Mack R.; Zborowski J.; Morris D.; Sebree T.; Shook S.; Wallin B.

A multiple fixed-dose, placebo-controlled trial with 'seroquel': an atypical antipsychotic
pp. 597-598(2)
Authors: Borison R.L.; Arvanitis L.A.; Miller B.G.

'Seroquel' (ICI 204,636): not different from placebo for EPS of prolactin
pp. 598-598(1)
Authors: W. W.H.; Arvanitis L.A.; Miller B.G.

Pharmacology of 'seroquel' (ICI 204,636): an atypical clozapine-like antipsychotic
pp. 598-598(1)
Author: Goldstein J.M.

Neuroleptic dosing with inpatient hispanic and asian schizophrenics
pp. 599-599(1)
Authors: Herrera J.; Sramek J.; Collazo J.; Tam R.; Dinn M.

Neuroleptic dosing with outpatient hispanic and asian schizophrenics
pp. 599-599(1)
Authors: Herrera J.; Sramek J.; Ruiz S.; P. C.; Valbrune A.; Abbas S.

Hippocampal and entorhinal hypoplasia in schizophrenia is associated with early onset
pp. 599-599(1)
Authors: Nasrallah H.A.; Olson S.C.

Cerebellar volume deficits in schizophrenia
pp. 600-600(1)
Authors: Deshmukh A.; Sullivan E.V.; Mathalon D.H.; Desmond J.E.; Matsumoto B.; K. O.L.; Pfefferbaum A.

A schizophrenia profile of regional cortical gray matter deficits
pp. 600-600(1)
Authors: Sullivan E.V.; K. O.L.; Mathalon D.H.; Marsh L.; Beal D.M.; Harris D.; Hoff A.; Faustman W.O.; Pfefferbaum A.

Landmark shape in schizophrenia: regional neuroanatomic correlates
pp. 600-600(1)
Authors: DeQuardo J.R.; Rajaprabhakaran R.; Bookstein F.L.; Brunberg J.A.; Tandon R.

Quantitative neuroanatomic study of schizophrenia: landmark-based analysis
pp. 601-601(1)
Authors: DeQuardo J.R.; Bookstein F.L.; Brunberg J.A.; Tandon R.

Three-dimensional visualization of the fronto-striato-thalamic circuitry in schizophrenia
pp. 601-601(1)
Authors: Buchsbaum M.S.; Hazlett E.; Haznedar M.; Newman A.; Germans M.; C. L.; Speigel-Cohen J.; T. W.; Schour D.; Siegel B.

Brain GMR in schizophrenics and controls matched for CPT score
pp. 601-602(2)
Authors: Siegel B.V.; Fleming K.; Nuechterlein K.H.; Buchsbaum M.S.

Loss of cerebral asymmetry in familial schizophrenia, a volumetric study using unbiased stereology
pp. 602-602(1)
Authors: Sharma T.; Lewis S.W.L.; Sigmundsson T.; Lancaster E.; Barta P.; Pearlson G.; Gurling H.; Murray R.M.M.

Schizotypal personality disorder: a MRI analysis of the whole brain
pp. 602-602(1)
Authors: Dickey C.C.; Shenton M.E.; Hirayasu Y.; Niznikiewicz M.; Fischer I.; Rhoads R.; Voglmaier M.M.; Seidman L.; McCarley R.W.

Reduced subcortical brain volumes in nonpsychotic siblings of schizophrenic patients
pp. 602-602(1)
Authors: Seidman L.J.; Faraone S.V.; Goldstein J.M.; Goodman J.M.; Matsuda G.; Kremen W.S.; Kennedy D.N.; Makris N.; Caviness V.S.; M. T.T.

Gray matter and white matter volume loss in anorexia nervosa
pp. 603-603(1)
Authors: Zipursky R.B.; Lambe E.K.; Goldbloom D.; Ridgley J.; Mikulis D.J.; Katzman D.K.

A pet study of bulimia nervosa reveals caudate hypermetabolism
pp. 603-603(1)
Authors: Klein E.A.; Blinder B.J.; J. C.W.; Hagman J.O.; Buchsbaum M.S.

Hypofrontality in major depressive disorder: relationship to psychiatric symptoms
pp. 603-603(1)
Authors: Galynker I.; Cai J.; Dutta E.; Serseni D.; Miner C.; Ongseng F.; Gallagher R.

Metabolic patterns associated with depressive symptoms in schizophrenia
pp. 604-604(1)
Authors: Kohler C.; Gur R.C.; Mozley L.H.; Swanson C.L.; Gur R.E.

FDOPA uptake in schizophrenia: a pet study
pp. 604-604(1)
Authors: Potkin S.G.; J. C.W.; Klein E.A.; Khosla N.; Najafi A.; LaCasse L.

Sex differences in pet FDOPA uptake
pp. 604-604(1)
Authors: Klein E.A.; J. C.W.

The effects of metabolic and cognitive stress on cerebral blood flow
pp. 604-605(2)
Authors: Elman I.; Wiesenfeld N.; T. P.S.; Malhotra A.K.; Pickar D.; Breier A.

Brain metabolism and sleep deprivation: a pet study
pp. 605-605(1)
Authors: J. C.W.; Klein E.A.; Gillin J.C.; Keator D.

Prefrontal-thalamic network for sensory gating in normal individuals
pp. 605-605(1)
Authors: Hazlett E.A.; Buchsbaum M.S.; Haznedar M.M.; Germans M.; Machac J.; Knesaurek K.; Vallabhajosula S.

Age and sex differences in human brain MU opioid receptor binding measured by pet
pp. 605-606(2)
Authors: Zubieta J.K.; Smith Y.R.; Ravert H.T.; Dannals R.F.; Frost J.J.

Cortical function in schizophrenia during blood flow activation
pp. 606-606(1)
Authors: Taylor S.F.; Tandon R.; Koeppe R.A.

Caudate nucleus and putamen abnormalities in pediatric OCD
pp. 606-606(1)
Authors: Rosenberg D.; Keshavan M.; Bagwell W.; Seymour A.; O'Hearn K.; Dick E.; Birmaher B.; Sweeney J.

A pet study of pet FDOPA uptake in abstaining cocaine addicts
pp. 606-606(1)
Authors: Bell K.M.; Klein E.A.; J. C.W.; Widmark C.B.; Najafi A.; Keator D.

A pet study of FDG metabolism in abstaining cocaine addicts
pp. 607-607(1)
Authors: J. C.W.; Klein E.A.; Bell K.M.; Widmark C.B.

Plasticity and cognitive disorders
pp. 607-607(1)
Authors: Gazzaniga M.S.; Green R.L.

Imaging memory systems in the normal human brain
pp. 608-608(1)
Author: Raichle M.E.

Neural systems underlying learning and memory
pp. 608-608(1)
Author: Damasio A.R.

Selective pharmacological limbic activation: phenomenology and blood-flow
pp. 608-608(1)
Authors: Servan-Schreiber D.; Perlstein W.M.; Cohen J.; Mintun M.

Context processing disturbances in schizophrenia: empirical test of a theoretical model
pp. 608-609(2)
Authors: Cohen J.D.; Barch D.M.; Servan-Schreiber D.; Carter C.S.

Magnetic resonance spectroscopic inestigations of affective disorders
pp. 609-609(1)
Author: Kato T.

¹H MRS investigation of panic disorder
pp. 609-609(1)
Authors: Dager S.R.; Richards T.L.; Marro K.I.; Strauss W.; Heidi A.; Artru A.A.; Posse S.

Proton MRS of human basal ganglia during acute cocaine administration
pp. 609-610(2)
Authors: Christensen J.D.; Kaufman M.J.; Rose S.L.; Mendelson J.H.; Lukas S.E.; Moore C.M.; Cohen B.M.; Renshaw P.F.

Functional magnetic resonance studies of brain activation
pp. 610-610(1)
Author: Posse S.

Maintenance treatment for schizophrenia
pp. 610-610(1)
Author: Kane J.

Maintenance treatment for panic disorder
pp. 610-610(1)
Author: Gorman J.M.

Maintenance treatment for obsessive-compulsive disorder
pp. 610-610(1)
Authors: Hollander E.; Cherkasky S.; C. W.; Grossman R.; DeCaria C.M.; Aronowitz B.

Relapse prevention strategies in the treatment of alcoholism
pp. 611-611(1)
Author: O'Malley S.S.

Antidepressant maintenance medications: a critical review
pp. 611-611(1)
Author: Greden J.F.

How neurons die
pp. 611-611(1)
Author: Coyle J.T.

Neurodegeneration in schizophrenia: a possible animal model?
pp. 611-612(2)
Authors: Bardgett M.E.; Csernansky J.G.

Cognitive impairment in elderly schizophrenics: phenomenology, longitudinal course, and neuropathology
pp. 612-612(1)
Authors: Mohs R.C.; Harvey P.D.; Davidson M.

The dementia of schizophrenia: antemortem and postmortem studies
pp. 612-612(1)
Authors: Gur R.E.; Arnold S.E.; Moberg P.J.; Petty R.G.; Gur R.C.; Trojanowski J.Q.

Early intervention in schizophrenia improves the long-term course of the illness
pp. 612-612(1)
Author: Wyatt R.J.

Mood and reproductive hormones, an overview
pp. 612-613(2)
Author: Halbreich U.

Reproductive hormones and mood in women
pp. 613-613(1)
Authors: Rubinow D.R.; Schmidt P.J.

Reproductive hormones as adjuncts to psychotropic medications
pp. 613-613(1)
Author: Stahl S.M.

Clinical evaluation for studies of gonadal hormones and mood
pp. 613-613(1)
Author: Endicott J.

Linkage studies in Irish High-Density Schizophrenia Families
pp. 614-614(1)
Authors: Kendler K.S.; Straub R.E.; MacLean C.J.; Walsh D.

A search for schizophrenia genes by affected sib-pair analysis
pp. 614-614(1)
Authors: Wildenauer D.B.; Schwab S.G.; Eckstein G.; Hoenig S.; Albus M.; Hallmayer J.; Borrmann M.; Lichtermann D.; Fimmers R.; Ebstein R.P.; Lerer B.; Risch N.; Maier W.

Schizophrenia loci: data of the JHU collaborative group
pp. 614-614(1)
Authors: Pulver A.; Antonarakis S.; Blouin J.; Ton C.; Housman D.; Karayiorgou M.; Wolyniec P.; Lasseter V.; Nestadt G.; DeMarchi N.; Loetscher E.; Luebbert H.; Kazazian H.; Williams S.

Evidence for a chromosome 18 bipolar susceptibility locus
pp. 614-614(1)
Authors: Berrettini W.; Ferraro T.; Goldin L.; DeteraWadleigh S.; Nurnberger J.; Gershon E.

Progress in the search for Schizophrenia susceptibility genes
pp. 615-615(1)
Authors: Byerley W.; H.-G. H.; Gottesman I.I.; Moises H.W.; L. Y.; Kristbjarnarson H.; Macciardi F.; Arolt V.; Blackwood D.; Aschauer H.N.; Weissenbach J.; Schwinger E.; Wetterberg L.; Helgason T.

Dana consortium on the genetic basis of manic depressive illness: chromosome 18 update
pp. 615-615(1)
Authors: DePaulo J.R.; Stine O.C.; McMahon F.

Linkage studies of bipolar disorder to chromosome 18 markers
pp. 615-615(1)
Authors: Nothen M.M.; Cichon S.; Craddock N.; Albus M.; Maier W.; Lichtermann D.; Weigelt B.; Franzek E.; Rietschel R.; Korner J.; Fimmers R.; Propping P.

Release and inactivation of endogenous cannabinoid substances
pp. 615-616(2)
Authors: Piomelli D.; Beltramo M.; Cadas H.; Di Tomaso E.; Stella N.

Neuropsychological deficits in marijuana smokers
pp. 616-616(1)
Authors: Yurgelun-Todd D.A.; Gruber S.A.; Pope H.G.

Withdrawal from chronic cocaine in rats: a model of depression
pp. 616-616(1)
Authors: Baumann M.H.; Rothman R.B.

Individual differences in cortical and subcortical GABA_A binding and behavior
pp. 616-616(1)
Authors: Gruen R.J.; Wenberg K.; Selim M.; Friedhoff A.J.; Bradberry C.W.

Alcoholism and age interact in their effects on brain function
pp. 617-617(1)
Authors: Ford J.M.; Mathalon D.H.; Rosenbloon M.J.; Lim K.O.; Pfefferbaum A.

The prediction of alcoholism a decade later
pp. 617-617(1)
Author: Schuckit M.A.

The effect of substance abuse on the course of bipolar disorder
pp. 617-617(1)
Authors: Dunner D.L.; Feinman J.

Growth hormone response to sumatriptan (5-HT1D agonist) challenge in sad: effects of light therapy
pp. 617-618(2)
Authors: Yatham L.N.; Lam R.W.; Zis A.P.

Brofaromine in social phobia--recent findings from a US trial
pp. 618-618(1)
Authors: Brofaromine Investigator's Group; Katz R.J.; Lott M.

Controlled study of antidepressant treatment of postpartum depression
pp. 618-618(1)
Authors: Epperson C.N.; McDougle C.J.; Ward-O'Brien D.; Price L.H.

Sequential studies of the treatment of mania
pp. 618-618(1)
Authors: Small J.G.; Klapper M.H.; Milstein V.; Marhenke J.D.; Small I.F.

Double-blind comparison of sexual dysfunction on imipramine and paroxetine
pp. 618-619(2)
Authors: Ontiveros A.; Valdes M.; Costilla A.

Double-blind study of double depression response to antidepressants
pp. 619-619(1)
Authors: Perez M.; Ontiveros A.

Double-blind comparison of amitriptyline and fluoxetine efficacy and tolerance
pp. 619-619(1)
Authors: Ontiveros A.; Brandy F.; Costilla A.

CI-988, a cholecystokinin-B antagonist, in panic disorder
pp. 619-620(2)
Authors: Pande A.C.; Greiner M.; Bammert-Adams J.; Pierce M.W.

Benzodiazepine sensitivity in panic and obsessive-compulsive disorders
pp. 620-620(1)
Authors: Roy-Byrne P.; Wingerson D.; Radant A.; Greenblatt D.; Cowley D.

Daytime sleepiness in young adults
pp. 620-620(1)
Authors: Breslau N.; Andreski P.; Rosenthal L.; Roth T.

Comparison of clomipramine vs. fenfluramine challenges
pp. 620-620(1)
Authors: Nicholas L.M.; Naftolowitz D.F.; Bebchuk J.M.; Heine A.D.; Ekstrom R.D.; Mason G.A.; Golden R.N.; Tancer M.E.

Dawn simulation treatment of abstinent alcoholics with winter depression
pp. 620-621(2)
Authors: Avery D.H.; Bolte M.A.; Ries R.K.

Side effect profile of venlafaxine in children and adolescents
pp. 621-621(1)
Authors: Mandoki M.; Tapia M.R.; Tapia M.A.; Sumner G.; Parker J.; Jacobs M.

Behavioral effects of venlafaxine in children and adolescents
pp. 621-621(1)
Authors: Mandoki M.; Tapia M.R.; Tapia M.A.; Sumner G.; Parker J.; Jacobs M.

Anticonvulsants and lithium in ''mixed'' vs. ''pure'' mania
pp. 621-622(2)
Authors: Goldberg J.F.; Leon A.C.; Garno J.L.; Kocsis J.H.

A bridging study of lesopitron in generalized anxiety disorder
pp. 622-622(1)
Authors: Sramek J.J.; Cutler N.R.; Marion-Landais G.; Jensen C.M.; Kurtz N.M.; Carrington A.T.

An open label trial of venlafaxine in adults with attention deficit disorder
pp. 622-622(1)
Authors: Adler L.A.; Resnick S.; Kunz M.; Devinsky O.

Paradoxical invigoration through sleep deprivation
pp. 622-623(2)
Authors: Szuba M.P.; Dinges D.F.; Baxter L.R.; Ball W.A.; O'Sullivan K.

Comparative effects of nefazodone & fluoxetine on sleep in outpatients with major depressive disorder
pp. 623-623(1)
Authors: Armitage R.; Rush A.J.; Gillin J.C.; Moldofsky H.

Antidepressant response to oral pulse loading with clomipramine
pp. 623-623(1)
Authors: Dube S.; Perel J.M.; Miewald J.; Kupfer D.J.

The role of the serotonergic system in seasonal affective disorder
pp. 623-624(2)
Authors: Neumeister A.; Praschak-Rieder N.; Hesselmann B.; Tauscher J.; Rao M.L.; Kasper S.

Ondansetron in social phobia
pp. 624-624(1)
Authors: Grunes M.S.; Yaryura-Tobias J.A.; Neziroglu F.A.

Reduced heart rate response to nortriptyline in females with unipolar depression
pp. 624-624(1)
Authors: Pomara N.; Deptula D.; Nolan K.; Tun H.; Singh R.; Leviste F.; Cooper T.B.

Differential effects of alprazolam and lorazepam on plasma cortisol in normal elderly
pp. 624-625(2)
Authors: Pomara N.; Deptula D.; Nolan K.; Tun H.; Singh R.; Leviste F.; Ritchie J.; Greenblatt D.J.; Nemeroff C.B.

An open-label study of fluvoxamine in body dysmorphic disorder
pp. 625-625(1)
Authors: Phillips K.A.; McElroy S.L.

Sex differences in the response to pharmacotherapy among early onset dysthymics
pp. 625-625(1)
Authors: Yonkers K.A.; Halbreich U.; Rush A.J.; Kornstein S.; Pearlstein T.; Stone A.

The effect of the CCK-B receptor antagonist CI-988 on CCK-4 induced panic attacks
pp. 625-626(2)
Authors: van Megen H.J.G.M.; Westenberg H.G.M.; Den Boer J.A.; van Es-Radhakishun F.

Do the antidepressants have anxiogenic action?
pp. 626-626(1)
Authors: Allikmets L.; Matto V.; Harro J.

Mechanism of sexual dysfunction in alcohol dependence: a pudendal sep study
pp. 626-626(1)
Authors: J. S.C.; H. S.H.; H. J.J.

Reduced blue cone ERG in cocaine patients
pp. 626-626(1)
Authors: Roy A.; Roy M.; Williams J.; Wineberger L.; Smelson D.

Neuropsychological assessments in detoxified alcoholics
pp. 627-627(1)
Authors: I. W.C.; S. J.K.; K. Y.W.

CSF monoamine metabolites in alcoholics with and without nicotine addiction
pp. 627-627(1)
Authors: Ragan P.W.; George D.T.; Shoaf S.; Eckardt M.; Linnoila M.

Neural mechanisms underlying alcohol's reinforcing properties
pp. 627-627(1)
Authors: Ownby R.L.; Mason B.J.

The effect of naltrexone on diazepam intoxication in social drinkers
pp. 628-628(1)
Authors: Swift R.M.; Davidson D.; Rosen S.; Fitz E.

Sweet liking/novelty seeking interactions predict a diagnosis of alcoholism
pp. 628-628(1)
Authors: Janowsky D.; Kampov A.; Garbutt J.C.

Hallucinogen and other illicit drug uses increases in the USA
pp. 628-628(1)
Authors: Johnson C.R.; Gold M.S.; Gleaton T.J.

Tobacco and marijuana use increases in junior and senior high school students
pp. 629-629(1)
Authors: Gold M.S.; Gleaton T.J.

Chronic corticosterone on mesocortical dopamine utilization
pp. 629-629(1)
Authors: Lindley S.E.; D. L.W.; Schatzberg A.F.

Regulation of hippocampal dopamine receptors by clozapine and haloperidol
pp. 629-629(1)
Authors: Ritter L.M.; Meador-Woodruff J.H.

Mesostriatal, mesolimbic and mesocortical dopamine neurons in primates
pp. 629-630(2)
Authors: Williams S.M.; Goldman-Rakic P.S.

Sensory gating in a computer model of the CA3 neural network of the hippocampus
pp. 630-630(1)
Authors: Flach K.A.; Gerhardt G.A.; Freedman R.; Adler L.E.

Elevated cholecystokinin mRNA in dorsolateral prefrontal cortex in suicides
pp. 630-630(1)
Authors: Bachus S.E.; Hyde T.M.; Herman M.M.; Kleinman J.E.

Differentiating dopamine D2 ligands by their sensitivities to modification of CYS118
pp. 630-631(2)
Authors: Javitch J.A.; D. F.; J. C.

Adenosylation of the dopamine D₄ receptor causes spontaneous activity
pp. 631-631(1)
Authors: Kramer M.L.; Kotb M.; Deth R.C.

Methyl donation by D₄ dopamine receptors in phospholipid methylation
pp. 631-631(1)
Authors: Deth R.C.; D. L.; Wick P.F.

High resolution scatchard analysis of the D1 receptor in the rat medial prefrontal cortex
pp. 631-631(1)
Authors: Davidoff S.A.; Benes F.M.

Differential localization of D₂, D₃, and D₄ MRNA in midgestational human forebrain by in situ hybridization
pp. 632-632(1)
Authors: Unis A.S.; Roberson M.D.; Hill K.; Hamblin M.W.; Dorsa D.M.

Biosynthesis of the dopamine D1, D4, and D5 receptor polypeptides
pp. 632-632(1)
Authors: Bergson C.; Lidow M.; Goldman-Rakic P.; Levenson R.

Hippocampal gating of cortical throughput in the nucleus accumbens: modulation by dopamine
pp. 632-632(1)
Authors: O'Donnell P.; Grace A.A.

[³H]WIN 35428 and [¹²⁵I]RTI-55 binding to wild type and mutant dopamine transporter
pp. 633-633(1)
Authors: Little K.Y.; DelProposto Z.S.; Mulroney S.

MK-801 differentially regulates dopamine receptor mRNA in hippocampus
pp. 633-633(1)
Authors: Healy D.J.; Meador-Woodruff J.H.

Is circadian variation of plasma HVA related to its renal excretion?
pp. 633-633(1)
Authors: Stroe A.; Amin F.; Kahn T.; Knott P.

Control of renal factors in plasma HVA measurements
pp. 633-634(2)
Authors: Amin F.; Kahn T.; Knott P.

Cocaine effects on dopamine transporter mRNA in human users
pp. 634-634(1)
Authors: Little K.Y.; McLaughlin D.P.; McFinton P.R.; Livermore C.S.; Watson S.J.; Cassin B.P.

Proton magnetic resonance spectroscopic imaging in drug free patients with schizophrenia: regional neuronal damage
pp. 634-634(1)
Authors: Bertolino A.; Callicott J.H.; Elman I.; Duyn J.H.; Tedeschi G.; Frank J.A.; Pickar D.; Weinberger D.R.

Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia and normal controls
pp. 634-635(2)
Authors: Bertolino A.; Callicott J.H.; Nawroz S.; Knable M.B.; Mattay V.S.; Duyn J.H.; Tedeschi G.; Frank J.A.; Weinberger D.R.

Proton magnetic resonance study of the hippocampus in schizophrenia
pp. 635-635(1)
Authors: Kegeles L.S.; Kaufmann C.A.; S. C.; Gorman J.; Mann J.J.; Malaspina D.

Proton magnetic resonance spectroscopic imaging in a monkey model of schizophrenia: preliminary results
pp. 635-635(1)
Authors: Bertolino A.; Saunders R.C.; Frank J.A.; Weinberger D.R.

Phosphorous-31 magnetic resonance spectroscopy of the basal ganglia in depressed subjects
pp. 635-636(2)
Authors: Moore C.M.; Christensen J.D.; Lafer B.; Fava M.; Renshaw P.F.

Development of auditory continuous performance tasks for functional MRI
pp. 636-636(1)
Authors: Seidman L.J.; Breiter H.; Goldstein J.M.; Goodman J.M.; Woodruff P.; O'Craven K.; Savoy R.; Kennedy D.N.; Baker J.; K. K.; M. T.T.; Rosen B.

3-D fMRI of working memory in schizophrenia
pp. 636-636(1)
Authors: Callicott J.H.; Tallent K.; Bertolino A.; Ramsey N.; Santha A.; Knable M.; Coppola R.; Goldberg T.; Mattay V.; van Gelderen P.; Frank J.A.; Moonen C.T.W.; Weinberger D.R.

Functional MRI of effortful attention in humans
pp. 636-637(2)
Authors: Breiter H.C.; Seidman L.J.; Goodman J.M.; Goldstein J.M.; O'Craven K.M.; Weisskoff R.M.; Woodruff P.W.R.; Savoy R.; Jiang A.; Kennedy D.; Kennedy W.; M. T.T.; Rosen B.R.

Cortical responses to threat-related words in normal subjects and patients with panic disorder: an fMRI study
pp. 637-637(1)
Authors: Maddock R.J.; Buonocore M.H.; Zhu D.

Frontal cortex activation increases with working memory load as measured by functional MRI (fMRI)
pp. 637-637(1)
Authors: Manoach D.S.; Schlaug G.; Siewart B.; Bly B.M.; Benfield A.; Edelman R.R.; Warach S.; Darby D.G.

Reversed planum temporale asymmetry in schizophrenia - a replication study
pp. 637-638(2)
Authors: Pearlson G.; Barta P.; Pulver A.; Powers R.; Casanova M.; Petty R.; Frangou S.

Temporal lobe changes distinguish schizophrenia from bipolar disorder
pp. 638-638(1)
Authors: Pearlson G.; Barta P.; Tune L.; Tien A.; Chase G.

Functional magnetic resonance imaging and schizophrenia
pp. 638-638(1)
Authors: Buckley P.F.; Lewin J.S.; Friedman L.; D. W.; Miller D.A.; Thompson L.A.; Klein S.K.; Wise A.L.; Hedera P.; Freidland R.; Meltzer H.Y.

Methods for planum temporale measurement: their importance for schizophrenia
pp. 638-639(2)
Authors: Barta P.; Honeycutt N.; Pearlson G.

MRI volume and localization of Heschl's gyri in schizophrenia
pp. 639-639(1)
Authors: Reite M.; Rojas D.C.; Teale P.; Sheeder J.; Simon J.

A quantitative volumetric MRI study of the brainstem and cerebellum in schizophrenia
pp. 639-639(1)
Authors: Levitt J.J.; Donnino R.; Shenton M.E.; Kikinis R.; Jolesz F.A.; McCarley R.W.

The parietal lobes in schizophrenia: a quantitative MR study
pp. 639-639(1)
Authors: Donnino R.; Shenton M.E.; Iosifescu D.; Hirokazu O.; Wible C.G.; Kikinis R.; Jolesz F.A.; McCarley R.W.

Automated measurement of subcortical brain MR structures in schzophrenia
pp. 640-640(1)
Authors: Iosifescu D.V.; Shenton M.E.; Kikinis R.; Dengler J.; Warfield S.K.; McCarley R.W.

Cluster analysis of MRI regional brain volumes in schizophrenia
pp. 640-640(1)
Authors: Mathalon D.H.; Marsh L.; Lim K.O.; Pfefferbaum A.

Autocovariance based analysis of functional MRI data
pp. 640-641(2)
Authors: Maas L.C.; Frederick B.d.; Yurgelun-Todd D.A.; Renshaw P.F.

Decoupled rotational and translational image registration for functional MRI data sets
pp. 641-641(1)
Authors: Maas L.C.; Frederick B.d.; Renshaw P.F.

Cocaine reduces cerebral blood volume in humans: detection with DSC MRI
pp. 641-641(1)
Authors: Kaufman M.J.; Levin J.M.; Christensen J.D.; Lukas S.E.; Mendelson J.H.; Maas L.C.; Rose S.L.; Cohen B.M.; Renshaw P.F.

Dynamic contrast MRI of cerebral blood volume compared with SPECT in Alzhemer's disease
pp. 641-641(1)
Authors: Harris G.J.; Lewis R.F.; Satlin A.; English C.D.; Scott T.M.; Yurgelun-Todd D.A.; Renshaw P.F.

Determination of salivary cortisol by non-radioisotopic immunoassay
pp. 642-642(1)
Authors: J. K.Y.; Moss H.B.; Sokulski D.E.; Kirillova G.P.

Neuroendocrine abnormalities in psychiatric patients: a multivariate study
pp. 642-642(1)
Authors: Duval F.; Mokrani M.C.; Crocq M.A.; Bailey P.; Diep T.S.; Macher J.P.

Neuroendocrine correlates of antipsychotic response in schizophrenia
pp. 642-642(1)
Authors: Duval F.; Mokrani M.C.; Crocq M.A.; Bailey P.; Diep T.S.; Macher J.P.

HPT and HPA axis dysfunction in depression: DA, NA, and 5HT correlates
pp. 643-643(1)
Authors: Duval F.; Mokrani M.C.; Crocq M.A.; Bailey P.; Diep T.S.; Macher I.P.

Noradrenergic and thyroid axis dysfunction in depression
pp. 643-643(1)
Authors: Duval F.; Mokrani M.C.; Crocq M.A.; Bailey P.; Diep T.S.; Macher J.P.

The role of GHRH in normal and pathological sleep regulation
pp. 643-643(1)
Authors: Steiger A.; Frieboes R.-M.; Murck H.; Guldner J.; Schier T.; Holsboer F.

Sleep endocrine effects of neuropeptide (NPY) in men reveal a GABA_A-agonistic action
pp. 643-644(2)
Authors: Antonijevic I.A.; Bohlhalter S.; Murck H.; Frieboes R.M.; Schier T.; Steiger A.

Gonadal steroid levels and memory function in infertile women
pp. 644-644(1)
Authors: Soleymani R.M.; Keenan P.A.; Ginsburg K.A.

A longitudinal study of HPA axis dysfunction in Alzheimer's disease
pp. 644-644(1)
Authors: Lawlor B.A.; Swanwick G.; Coen R.; Walsh B.J.; Coakley D.

Cognitive and pet studies of postmenopausal women
pp. 644-644(1)
Authors: Chakravorty S.G.; Lockwood A.; Halbreich U.

Menstrual cycle effects on the auditory brainstem response
pp. 645-645(1)
Authors: Tasman A.; Maiste A.; Hahn T.A.

Neuroendocrinological impacts of glucoprivic stress
pp. 645-645(1)
Authors: Elman I.; Bir C.; Pickar D.; Breier A.

A protocol for an animal model for neuroimmunologic psychiatric disease
pp. 645-645(1)
Authors: Black J.L.; Griesmann G.E.; Lennon V.A.; Snutch T.P.

Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder
pp. 645-646(2)
Authors: FitzGerald M.; Malone K.; Harrison W.; MacBride P.A.; Endicott J.; Mann J.J.

Mechanism of efficacy of fluoxetine in premenstrual syndrome
pp. 646-646(1)
Authors: Roca C.A.; Rosenstein D.L.; Schmidt P.J.; Danaceau M.A.; Greenberg B.; Murphy D.L.; Rubinow D.R.

Course of psychotic disorders in women: influence of menstrual cycle phase
pp. 646-646(1)
Author: Schechter D.

Role of ovarian steroids in modulating mood in premenstrual syndrome
pp. 646-646(1)
Authors: Schechter D.; Strasser T.J.; Endicott J.; Petkova E.; Nee J.

Hyperactivation of the HPT axis in depression-new evidence
pp. 647-647(1)
Authors: Mourilhe P.R.; Stokes P.E.; Barsdorf A.I.; Ombid H.

Neuroendocrine responses to the citalopram challenge test in depression
pp. 647-647(1)
Authors: Kapitany T.; Heszelmann B.; Schindler S.D.; Barnas C.; Sieghart W.; Kasper S.

Blunted neuroendocrine response to citalopram challenge in diabetes (Type 1)
pp. 647-647(1)
Authors: Schindler S.D.; Kapitany T.; Hellelmann B.; Barnas C.; Sieghart W.; Kasper S.

Neuroendocrine-immune interactions in the every day life of healthy volunteers
pp. 647-648(2)
Authors: Kronfol Z.; Q. Z.; Hariharan M.; V. K.S.; Nair M.

Lower level of estradiol in postpartum depression among Chinese women
pp. 648-648(1)
Authors: R. B.L.; H. C.K.; B. L.Y.; F. M.C.; T. L.Y.; K. E.H.

Comorbidity of premenstrual depression and postpartum blues among Chinese women
pp. 648-648(1)
Authors: H-C. K.; L-R. L.; F-M. C.; R-B. L.; K-E. H.

ACTH & -endorphin over the menstrual cycle in women with PMS & controls
pp. 648-649(2)
Authors: Bloch M.; Schmidt P.J.; T-P S.; Tobin M.B.; Rubinow D.R.

Alternative strategies for quantifying speed of response in major depression
pp. 649-649(1)
Authors: Nobler M.S.; Sackeim H.A.; Prudic J.; Devanand D.P.; Moeller J.R.

Prolactin response to ECT: effects of electrode placement and dosage
pp. 649-649(1)
Authors: Lisanby S.H.; Devanand D.P.; Prudic J.; Nobler M.S.; Fitzsimons L.; Sackeim H.A.

Effect of ECT on plasma homovanillic acid in elderly major depression: preliminary findings
pp. 649-650(2)
Authors: H. L.; Lawlor B.A.

VBR in depression: does it predict symptom severity and response to ECT?
pp. 650-650(1)
Authors: Tomori O.; DeQuardo J.R.; Tandon R.

High-dose versus threshold methods of stimulus dosing in ECT
pp. 650-650(1)
Authors: Kumar-Gill A.; Tandon R.; DeQuardo J.R.; Ghaziuddin N.; Becks L.; Miller A.

Relevance of EEG manifestations during electroconvulsive therapy
pp. 650-650(1)
Authors: Maixner D.; Tandon R.; DeQuardo J.R.; Ghaziuddin N.; Miller A.; Becks L.

Distinct memory deficits from bilateral vs. unilateral electroconvulsive seizures
pp. 651-651(1)
Authors: Francis A.; Decena E.; McCaughran J.; Fochtmann L.

Differing relationship of cholinergic and catecholaminergic neurotransmission to sensory gating in schizophrenic patients, bipolar patients, and normal subjects
pp. 651-651(1)
Authors: Adler L.E.; Waldo M.C.; McRae K.A.; Cawthra E.; Nagamoto H.T.; Hoffer L.; Johnson M.; Gerhardt G.

Auditory evoked potentials in schizophrenia
pp. 651-651(1)
Authors: Boutros N.; Nasrallah H.; Leighty R.; Torello M.; Tueting P.; Olson S.

A parametric study of the rat N40 evoked response
pp. 652-652(1)
Authors: Boutros N.; Milana R.; Liu J.

Dissociation of P1/P50 subcomponent abnormalities in schizophrenia
pp. 652-652(1)
Authors: Erwin R.J.; Turetskty B.; Gur R.E.

Effect of nicotine and stage 2 sleep on auditory P50 gating in schizophrenia
pp. 652-652(1)
Authors: Griffith J.M.; O'Neill J.E.; Petty F.; Garver D.L.

The effects of clozapine treatment on auditory event-related potentials (aERP)
pp. 652-653(2)
Authors: Umbricht D.; Novak G.; Javitt D.; Pollack S.; Lieberman J.; Kane J.

Delayed visual processing ERP negativity (NA) in chronic schizophrenia
pp. 653-653(1)
Authors: Saito H.; Inosaka T.; Matsuoka H.; Sato M.; Steinhauer S.R.; van Kammen D.P.

ERP abnormalities in schizophrenia prior to neuroleptic treatment
pp. 653-653(1)
Authors: Hirayasu Y.; Asato N.; Ohta H.; Hokama H.; Arakaki H.; Ogura C.

Reduced long-latency positive activity in schizophrenia on a homograph task
pp. 653-654(2)
Authors: Salisbury D.F.; Shenton M.E.; McCarley R.W.; Sherwood A.R.; Fischer I.A.

P300 subcomponent abnormalities in siblings discordant for schizophrenia
pp. 654-654(1)
Authors: Turetsky B.; Colbath E.A.; Cannon T.D.; Gur R.E.

ERPS as a probe of language processing difficulties in schizophrenia spectrum disorders
pp. 654-654(1)
Authors: Niznikiewicz M.A.; Nestor P.G.; O'Donnell B.F.; Seidman L.; Dickey C.C.; Allard J.E.; Rhoades R.; McCarley R.W.; Shenton M.E.

Processing negativity in schizotypal university students
pp. 654-655(2)
Authors: Roth R.M.; Milovan D.; Baribeau J.

Mechanisms of auditory working memory dysfunction in schizophrenia
pp. 655-655(1)
Authors: Shelley A.M.; Javitt D.C.; Vaughan H.G.

ERP measures of visual spatial processing in schizophrenia
pp. 655-655(1)
Authors: O'Donnell B.F.; Ohta H.; McCarley R.W.; Hokama H.; Karapelou M.E.; Law S.E.

Visual memory deficits in schizophrenia: medication and ERP correlates
pp. 655-656(2)
Authors: Rabinowicz E.F.; Knight R.A.; Bruder G.; Owen D.R.; Gorman J.

Relationship between spectral characteristics of resting EEG and P50 gating
pp. 656-656(1)
Authors: Light G.A.; Geyer M.A.; Clementz B.; Schwarzkopf S.B.; Braff D.L.

Cognitive psychophysiology in anxiolytic drug research
pp. 656-656(1)
Authors: Semlitsch H.V.; Anderer P.; Saletu B.

Psychiatric correlates of EEG asymmetries in major depression
pp. 656-656(1)
Authors: Lee G.P.; Brown T.M.; Sharon D.; Haverstock S.L.

EEG resonant responses to photic stimulation following SDZ MAR-327 treatment
pp. 657-657(1)
Authors: Jin Y.; Potkin S.G.; Cezar C.

The effects of clozapine on sleep EEG in bipolar illness
pp. 657-657(1)
Authors: Armitage R.; Suppes T.; Cole D.; Rush A.J.

Hypofrontality in drug-free schizophrenic patients revealed by EEG coherence analysis
pp. 657-657(1)
Authors: Tauscher J.; Rappelsberger P.; Neumeister A.; Kasper S.

Brain EEG abnormalities in 300 hospitalized preadolescents
pp. 657-658(2)
Authors: Gehm N.K.; Nasrallah H.A.

Specific hippocampal atrophy identifies early alzheimer's dementia
pp. 658-658(1)
Authors: Convit A.; de Leon M.J.; Tarshish C.; De Santi S.; Rusinek H.; George A.E.

The use of RNA fingerprinting technique in the neuropsychiatry research
pp. 658-658(1)
Authors: Yamada M.; Yamada M.; Hisamitsu T.; Uchida N.; Richelson E.

In vivo proton MRS of Alzheimer's disease in the parietal and temporal lobes
pp. 658-658(1)
Authors: Frederick B.d.; Satlin A.; Yurgelun-Todd D.; Renshaw P.F.

Cognitive impairment in elderly depressed individuals with APOE &unknown;4
pp. 659-659(1)
Authors: Tupler L.A.; Krishnan K.R.R.; Ritchie J.C.; McDonald W.M.; Knight D.L.; Nemeroff C.B.; Carroll B.J.

The influence of ''silent'' cerebrovascular disease on measurement in Alzheimer's disease
pp. 659-659(1)
Authors: Lawlor B.A.; Swanwick G.; Coen R.; Walsh J.B.; Coakley D.

Regional cerebral blood flow in patients with dementia of Alzheimer's type: relationship to psychiatric symptoms
pp. 659-659(1)
Authors: Galynker I.; Vilkas N.; Dutta E.; Serseni D.; Finestone H.; Gallagher R.; Rosenthal R.

CSF epinephrine in aging and Alzheimer's disease
pp. 659-660(2)
Authors: Peskind E.R.; Elrod R.; Digiacomo L.; Veith R.C.; Raskind M.A.

Lateral and medial temporal lobe metabolic rate in Alzheimer's disease
pp. 660-660(1)
Authors: Shihabuddin L.; Buchsbaum M.S.; Harvey P.; Hazlett E.; Haznedar M.; Marin D.; Pandit N.; Spiegel-Cohen J.; C. T.W.; Abel L.; Ciaravolo T.; Machac J.; Knesaurek K.; Vallabhajosula S.; Fine E.; Mohs R.C.; Davis K.L.

Brain stimulation reverses cerebral metabolic reductions in Alzheimer disease
pp. 660-660(1)
Authors: Pietrini P.; Dani A.; Furey M.L.; Freo U.; Horwitz B.; Mentis M.; Alexander G.E.; Grady C.; Schapiro M.B.; Rapoport S.I.

Cognitive improvement in Alzheimer's disease: use of the CNTB in a trial of Xanomeline
pp. 660-661(2)
Authors: Cutler N.R.; Veroff A.E.; Bodick N.C.; Offen W.W.; Sramek J.J.

Phenotype of depression in alzheimer's disease (AD) with APOE genotype
pp. 661-661(1)
Authors: Cantillon M.; Barker W.; Harwood D.; Mullan M.; Duara R.

Basal ganglia morphology in geriatric mania
pp. 661-661(1)
Authors: Bocksberger J.P.; Young R.C.; Kalayam B.; Elkin C.; Alexopoulos G.S.

Circadian rest-activity rhythms in demented nondemented elders and their caregivers
pp. 661-661(1)
Authors: Pollak C.P.; Stokes P.E.; Mourilhe P.R.

Visual processing is abnormal in striate and association areas in alzheimer's disease
pp. 662-662(1)
Authors: Mentis M.J.; Horwitz B.; Grady C.; Alexander G.E.; Furey M.L.; Schapiro M.B.; Rapoport S.I.

Anticholinergic eye drops in differentiating alzheimer's disease and depression.
pp. 662-662(1)
Authors: Schweitzer I.; V. C.; Kabov J.; Ames D.; Vingrys A.; Tuckwell V.

Questionable dementia: clinical course and predictors of outcome
pp. 662-662(1)
Authors: Devanand D.P.; Folz M.; Gorlyn M.; Moeller J.R.; Stern Y.

Progress in epilepsy: psychiatric and psychopharmacologic advances
pp. 662-663(2)
Authors: Chapman D.P.; Giles W.H.

Post-operative mental status changes following anesthesia in children
pp. 663-663(1)
Authors: Martini D.R.; Mazurek A.; Mityas P.; Przybylo H.J.; Fanta K.B.; Suresh S.; Cote C.

DHEA-S and decline in HIV-1 associated cognitive/motor functioning
pp. 663-663(1)
Authors: Silva S.G.; Jackson E.; Chaisson N.; Stern R.A.; Golden R.N.; Petitto J.; Evans D.L.

Negative symptoms in medical and surgical patients undergoing intensive rehabilitation.
pp. 663-664(2)
Authors: Galynker I.; Salvit C.; Phillips E.; Focseneanu M.; Miner C.; Rosenthal R.

Validation of the DSM IV construct of minor depression in patients with stroke
pp. 664-664(1)
Authors: Paradiso S.; Robinson R.G.; Lamberty G.

Simulation for desensitization of children requiring MRI
pp. 664-664(1)
Authors: Rosenberg D.; Sweeney J.; Gillen J.; S. C.; Varanelli M.; O'Hearn K.; Erb P.; Davis D.; Thulborn K.

Prevalence of DSM-IV mood disorders in the general population of UK
pp. 664-664(1)
Authors: Ohayon M.M.; Priest R.G.; Guilleminault C.; Caulet M.

Prevalence of psychotropic drug consumption in the general population of UK
pp. 665-665(1)
Authors: Priest R.G.; Ohayon M.M.; Caulet M.

Acupuncture: physiological mechanisms and clinical application
pp. 665-665(1)
Authors: Ulett G.A.; Han S.P.

A biological basis for treating eating disorders
pp. 665-665(1)
Author: Kaye W.

Bulimia nervosa: which treatment is best?
pp. 665-666(2)
Author: Mitchell J.E.

Treatment of binge eating disorder
pp. 666-666(1)
Author: Agras S.

Anorexia nervosa: prevention of relapse
pp. 666-666(1)
Authors: Halmi K.A.; Mitchell J.; Agras S.